Kvartalsrapport Q3 2024

Automatiskt nyckeltalsindex

Detta är sökträffar och textkontext, inte verifierade eller normaliserade redovisningsvärden.

Fulltext

===== SIDA 1 =====

1 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
AstraZeneca 
12 November 2024 
9M and Q3 2024 results 
 
Upgrade to full year 2024 guidance underpinned by strong underlying growth momentum 
 
Revenue and EPS summary 
 
  9M 2024 % Change Q3 2024 % Change 
  $m  Actual  CER1  $m  Actual  CER  
- Product Sales  37,576   16   19   12,947   18   20   
- Alliance Revenue   1,498   49   50   559   48   50   
- Collaboration Revenue  108   (66) (66) 59   (39) (40) 
Total Revenue  39,182   16   19   13,565   18   21   
Reported EPS  $3.57   11   21   $0.92   4   17   
Core2 EPS  $6.12   5   11   $2.08   20   27   
 
Financial performance for 9M 2024 (Growth numbers at constant exchange rates) 
 
‒ Total Revenue up 19% to $ 39,182m, driven by a 19% increase in Product Sales and continued growth in 
Alliance Revenue from partnered medicines 
 
‒ Total Revenue growth from Oncology was 22%, CVRM 21%, R&I 24% and Rare Disease 14%  
 
‒ Core Product Sales Gross Margin3 of 82% 
 
‒ Core Operating Margin of 32% 
 
‒ Core Tax Rate of 20% 
 
‒ Core EPS increased 11% to $6.12. In the prior year period, Core EPS included gains totalling $953m from 
the disposal of Pulmicort Flexhaler US rights and updated contractual arrangements for Beyfortus 
 
‒ Guidance for FY 2024 Total Revenue and Core EPS growth at CER upgraded to high teens percentage 
growth 
 
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:  
  
"Our company has continued on its strong growth trajectory in the first nine months of 2024. Total Revenue and 
Core EPS were up 21% and 27% respectively in the third quarter, reflecting the increasing demand for our 
medicines across Oncology, BioPharmaceuticals and Rare Disease and supporting an upgrade to our full year 
2024 guidance. 
  
In the year to date we have announced the results for multiple positive high-value trials and are working to bring 
these new options to patients as quickly as possible. Additionally, the  quality and impact of our scientific 
research was well recognised this quarter with data for AstraZeneca medicines featuring in an unprecedented 
five Presidential Plenary sessions at the two major oncology conferences in September. 
  
We are highly encouraged by the broad -based underlying momentum we are seeing across our company in 
2024, and growth looks set to continue through 2025, providing a solid foundation to deliver on our 2030 
ambition. 
 
Finally, we take the matters in China very seriously. If requested we will fully cooperate with the authorities. We 
remain committed to delivering innovative life-changing medicines to patients in China." 
 
Key milestones achieved since the prior results announcement 
 
‒ Positive read-outs for Tagrisso plus Orpathys in EGFRm NSCLC with high levels of MET overexpression 
and/or amplification (SAVANNAH), Calquence in combination with venetoclax, with or without obinutuzumab 
 
1  Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between 
periods in 2024 vs. 2023. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) 
because they remove the effects of currency movements from Reported results. 
2  Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due 
to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between 
Reported EPS and Core EPS is provided in Table 11 and Table 12 in the Financial performance section of this document. 
3  The calculations for Reported and Core Product Sales Gross Margin exclude the impact of Alliance Revenue and Collaboration Revenue.

===== SIDA 2 =====

2 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
in previously untreated CLL (AMPLIFY), and the next generation propellan t for Breztri. Koselugo in adult 
patients with NF1-PN (KOMET), Tezspire in severe chronic rhinosinusitis with nasal polyps (WAYPOINT) 
 
‒ US approvals for Tagrisso in unresectable, Stage III EGFRm NSCLC (LAURA) and Imfinzi plus 
chemotherapy in resectable early -stage NSCLC (AEGEAN) and FluMist for self -administration. EU 
approvals for Imfinzi plus chemotherapy followed by Imfinzi alone in mismatch repair deficient endometrial 
cancer (DUO-E), Imfinzi plus chemotherapy followed by Lynparza and Imfinzi in mismatch repair proficient 
endometrial cancer (DUO -E) and Fasenra for EGPA  (MANDARA). China approvals for Enhertu in 
unresectable, locally adva nced or metastatic HER2-mutated NSCLC  (DESTINY-Lung02, DESTINY -
Lung05), Enhertu in locally advanced or metastatic HER2 -positive gastric or gastroesophageal junction 
adenocarcinoma (DESTINY-Gastric06), and Fasenra for severe eosinophilic asthma (MIRACLE) 
 
Guidance 
 
Given the strength of underlying Product Sales and Alliance Revenue, as well as increased confidence in 
achieving certain sales-based milestones, the Company raises its Total Revenue and Core EPS guidance for 
FY 2024 at CER. 
 
Total Revenue is expected to increase by a high teens percentage (previously a mid teens percentage) 
Core EPS is expected to increase by a high teens percentage (previously a mid teens percentage) 
 
‒ Other elements of the Income Statement are expected to be broadly in-line with the indications issued in the 
Company's H1 2024 earnings statement  
 
The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material 
elements of the Reported results, including any fair value adjustments arising on acquisition -related liabilities, 
intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements 
section regarding forward-looking statements at the end of this announcement. 
 
Currency impact 
 
If foreign exchange rates for October 2024 to December 2024 were to remain at the average rates seen in 
September 2024, it is anticipated that FY 2024 Total Revenue would incur a low single-digit percentage adverse 
impact compared to the performance at CER (unchanged from previous guidance), and Core EPS would incur 
a mid single -digit percentage adverse impact (unchanged from previous guidance). The Company 's foreign 
exchange rate sensitivity analysis is provided in Table 17. 
 
China 
 
As previously disclosed, t he Company is aware of a number of individual investigations by the Chinese 
authorities into current and former AstraZeneca employees . To the best of the Company's knowledge, the 
investigations include allegations of medical insurance fraud, illegal drug importation and personal information 
breaches. Recently Leon Wang, EVP International and AstraZeneca China President  was detained.  The 
Company has not received any notification that it is itself under investigation. If requested, AstraZeneca will fully 
cooperate with the Chinese authorities.  
 
Table 1: Key elements of Total Revenue performance in Q3 2024 
 
  % Change    
Revenue type   $m  Actual %  CER %    
Product Sales   12,947  18  20    
Alliance Revenue 
 
559  48  50    $49m Beyfortus (Q3 2023: $17m) 
 $361m Enhertu (Q3 2023: $266m) 
 $123m Tezspire (Q3 2023: $74m) 
Collaboration Revenue   59  (39) (40)   $56m Beyfortus (Q3 2023: $71m) 
Total Revenue   13,565  18  21    
Therapy areas  
 
$m  Actual % CER % 
  
Oncology  
 
5,569  19  22    Tagrisso up 14% (17% at CER), Calquence up 
24% (25% at CER), Enhertu Total Revenue up 
50% (55% at CER)

===== SIDA 3 =====

3 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
CVRM   3,159  18  20    Farxiga up 25% (27% at CER), Lokelma up 40% 
(42% at CER) 
R&I  
 
1,959  26  29    Breztri up 56% (57% at CER). Saphnelo up 63% 
(64% at CER), Tezspire up >2x, Symbicort up 
27% (31% CER) 
V&I   460  48  49    Beyfortus Total Revenue up 73% (72% at CER), 
FluMist up 34% (31% at CER) 
Rare Disease  
 
2,148  9  11   • Ultomiris up 33% (35% at CER), partially offset by 
decline in Soliris of 22% (18% at CER), Strensiq 
up 20% (21% at CER) and Koselugo up 37% 
(39% at CER)  
Other Medicines   270  (12) (8)   
Total Revenue   13,565  18  21    
Regions   $m  Actual % CER % 
  
US   6,008  23  23    
Emerging Markets   3,423  15  23    
- China   1,671  15  15    
- Ex-China Emerging Markets   1,752  16  31    
Europe   2,875  22  22    
Established RoW   1,260  (1) 4    
Total Revenue  13,565  18  21    
 
Key alliance medicines 
 
‒ Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited (Daiichi Sankyo) and 
AstraZeneca, amounted to $2,729m in 9M 2024 (9M 2023: $1,844m). 
 
‒ Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $843m in  9M 2024 (9M 
2023: $438m). 
 
Table 2: Key elements of financial performance in Q3 2024 
 
Metric  
 
Reported Reported 
change 
Core Core  
change 
 Comments4 
Total 
Revenue $13,565m 18% Actual      
21% CER $13,565m 18% Actual      
21% CER 
  See Table 1 and the Total Revenue section 
of this document for further details 
Product 
Sales Gross 
Margin  
76% -5pp Actual      
-4pp CER 81% Stable Actual      
and CER 
  Variations in Product Sales Gross Margin 
can be expected between periods, due to 
product seasonality (e.g. FluMist and 
Beyfortus sales are weighted to the second 
half of the year), foreign exchange 
fluctuations and other effects 
‒ Reported Product Sales Gross Margin 
impacted by PAAGR5 inventory related 
restructuring charges taken in the quarter 
R&D 
expense  $3,115m 21% Actual      
21% CER $3,068m 23% Actual      
24% CER 
 + Increased investment in the pipeline 
 Core R&D-to-Total Revenue ratio of 23%  
(Q3 2023: 22%) 
SG&A 
expense  $5,143m 7% Actual      
8% CER $3,605m 8% Actual      
9% CER 
 + Market development for recent launches and 
pre-launch activities 
 Core SG&A-to-Total Revenue ratio of 27% 
(Q3 2023: 29%) 
 
4  In Table 2, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a ‘+’ symbol next to a  comment 
related to the R&D expense indicates that the item resulted in an increase in the R&D spend relative to the prior year. 
5  Post Alexion Acquisition Group Review. In conjunction with the acquisition of Alexion, the Post Alexion Acquisition Group Review Group 
initiated a comprehensive review, aimed at integrating systems, structure and processes, optimising the global footprint and prioritising 
resource allocations and investments. These activities are expected to be substantially complete by the end of 2026.

===== SIDA 4 =====

4 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Other 
operating 
income and 
expense6  
$25m -65% Actual      
-61% CER $24m -65% Actual      
-61% CER 
 
 
Operating 
Margin 16% -1pp Actual      
Stable CER 32% +1pp Actual      
+2pp CER 
  See commentary above on Gross Margin, 
R&D, SG&A and Other operating income 
and expense 
Net finance 
expense  $274m -6% Actual      
-15% CER $329m 46% Actual      
35% CER 
 + New debt issued at higher interest rates 
+ Higher level of Net debt 
Tax rate 22% +5pp Actual      
+5pp CER 19% Stable Actual      
and CER 
  Variations in the tax rate can be expected 
between periods 
EPS $0.92 4% Actual      
17% CER $2.08 20% Actual      
27% CER 
  Further details of differences between 
Reported and Core are shown in Table 12 
 
Table 3: Pipeline highlights since prior results announcement 
 
Event Medicine Indication / Trial 
 
Event 
Regulatory 
approvals and other 
regulatory actions 
Tagrisso Unresectable, Stage III 
EGFRm NSCLC (LAURA) 
Regulatory approval (US) 
Imfinzi Primary advanced or 
recurrent endometrial 
cancer with mismatch 
repair deficiency (DUO-E) 
Regulatory approval (EU) 
Imfinzi + Lynparza Primary advanced or 
recurrent endometrial 
cancer with mismatch 
repair proficiency (DUO-E) 
Regulatory approval (EU) 
Imfinzi Resectable early-stage 
(IIA-IIIB) NSCLC 
(AEGEAN) 
Regulatory approval (US) 
Enhertu Locally advanced or 
metastatic HER2-positive 
gastric or 
gastroesophageal junction 
adenocarcinoma 
(DESTINY-Gastric06) 
Regulatory approval (CN) 
Enhertu Unresectable locally 
advanced or metastatic 
HER2m NSCLC 
(DESTINY-Lung02, 
DESTINY-Lung05) 
Regulatory approval (CN) 
Fasenra EGPA (MANDARA) Regulatory approval (US, EU) 
Fasenra Fasenra (MIRACLE) Regulatory approval (CN) 
FluMist Self-administration Regulatory approval (US) 
Regulatory 
submissions  
or acceptances* 
Tagrisso EGFRm NSCLC (Stage III 
unresectable) (LAURA) 
Regulatory submission (EU, 
JP, CN) 
Imfinzi Muscle-invasive bladder 
Cancer (NIAGARA) 
Regulatory submission (EU) 
Imfinzi NSCLC (neoadjuvant) 
AEGEAN 
Regulatory submission (JP) 
Imfinzi SCLC (limited stage) 
(ADRIATIC) 
Regulatory submission (US, 
EU, JP, CN) 
Calquence Mantle cell lymphoma (1st-
line) (ECHO) 
Regulatory submission (US, 
EU, JP) 
 
6  Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, continue to 
be recorded in Other operating income and expense in the Company’s financial statements.

===== SIDA 5 =====

5 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Calquence CLL (ELEVATE-TN) Regulatory submission (CN) 
Lynparza mCRPC (PROpel) Regulatory submission (CN) 
Enhertu HER2-low breast cancer 
(2nd-line) (DESTINY-
Breast06) 
Regulatory submission (US, 
EU, JP) 
Wainua Hereditary transthyretin-
mediated amyloid 
polyneuropathy (NEURO-
TTRansform) 
Regulatory submission (CN) 
Breztri and HFO1234ze Moderate to severe COPD Regulatory submission (EU) 
Sipavibart Prevention of COVID-19 
(SUPERNOVA) 
Regulatory submission (JP) 
Ultomiris NMOSD (CHAMPION-
NMOSD) 
Regulatory submission (CN) 
Phase III / 
registrational data 
readouts and other 
developments 
Tagrisso + Orpathys EGFRm NSCLC with high 
levels of MET 
overexpression and/or 
amplification (SAVANNAH) 
Clinically meaningful ORR 
Calquence fixed duration Chronic lymphocytic 
leukaemia (AMPLIFY) 
Primary endpoint met 
Fasenra Eosinophilic chronic 
rhinosinusitis with nasal 
polyps (ORCHID) 
Primary endpoint not met 
Tezspire Severe chronic 
rhinosinusitis with nasal 
polyps (WAYPOINT) 
Primary endpoint met 
Koselugo Adults with NF1-PN 
(KOMET) 
Primary endpoint met 
 
*US, EU and China regulatory submission denotes filing acceptance  
 
Upcoming pipeline catalysts 
 
For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, 
available on www.astrazeneca.com/investor-relations.html.  
 
Corporate and business development 
 
In October 2024, AstraZeneca entered into an exclusive license agreement with CSPC Pharmaceutical Group 
Ltd (CSPC) to advance the development of an early stage, novel small molecule Lipoprotein (a) (Lp(a)) disruptor 
that has the potential to offer additional benefits for p atients with dyslipidaemia. This further strengthens the 
company's cardiovascular portfolio to help address the major risk factors driving chronic cardiovascular disease. 
Under the terms of the agreement, AstraZeneca will receive access to  CSPC's pre -clinical candidate small 
molecule, YS2302018, an oral Lp(a) disruptor, with the aim of developing this as a novel lipid -lowering therapy 
with potential in a range of cardiovascular disease indications alone or in combination, including with 
AstraZeneca's oral small molecule PCSK9 inhibitor, AZD0780.  CSPC will receive an upfront payment of $100 
million from AstraZeneca. CSPC is also eligible to receive up to $1.92 billion for further development and 
commercialisation milestones plus tiered royalties. 
 
In October 2024, AstraZeneca entered into an agreement to out -license ALXN1840 (bis -choline 
tetrathiomolybdate), a drug candidate for Wilson disease to Monopar Therapeutics Inc (Monopar). Monopar will 
be responsible for all future global development and commercialisation activities. AstraZeneca will have a 9.9% 
beneficial ownership interest in Monopar upon issuance as well as an upfront cash payment of $4.0  million. 
AstraZeneca is also eligible to receive milestones and royalties. 
 
Sustainability highlights 
 
In September, AstraZeneca had a significant presence at Climate Week NYC and the 79th Session of the UN 
General Assembly in New York, with a delegation led by Pam Cheng, Executive Vice President of Global 
Operations and IT and Chief Sustainability Officer and  the company's US leadership. A programme of more 
than 50 engagements with governments, media, NGOs and the private sector focused on the interconnected

===== SIDA 6 =====

6 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
issues of the climate crisis, health equity and health system resilience and the Company 's commitment to 
contribute to more sustainable, resilient and equitable health systems. 
 
Conference call  
 
A conference call and webcast for investors and analysts will begin today, 12 November 2024 , at 14:00 UK 
time. Details can be accessed via astrazeneca.com. 
 
Reporting calendar  
 
The Company intends to publish its FY and Q4 2024 results on 6 February 2025. 
 
Operating and financial review 
 
All narrative on growth and results in this section is based on actual exchange rates, and financial figures are 
in US$ millions ($m), unless stated otherwise. The performance shown in this announcement covers the nine-
month period to 30 September 2024 ('the period ' or '9M 2024') compared to the nine-month period to 30 
September 2023 ('9M 2023'), or the three -month period to 30 September 202 4 ('the quarter ' or 'Q3 2024') 
compared to the three-month period to 30 September 2023 ('Q3 2023'), unless stated otherwise.  
 
Core financial measures, EBITDA, Net debt, Product Sales Gross Margin, Operating Margin and CER are non-
GAAP financial measures because they cannot be derived directly from the Group 's Condensed consolidated 
financial statements. Management believes that these non -GAAP financial measures, when provided in 
combination with Reported results, provide investors and analysts with helpful supplementary information to 
understand better the financial performance and position of the Group on a comparable basis from period to 
period. These non-GAAP financial measures are not a substitute for, or superior to, financial measures prepared 
in accordance with GAAP. 
 
Core financial measures are adjusted to exclude certain significant items:  
 
‒ Charges and provisions related to our global restructuring programmes  on our capitalised manufacturing 
assets and IT assets 
 
‒ Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges 
relating to IT assets 
 
‒ Other specified items, principally the imputed finance charge s and fair value movements  relating to 
contingent consideration on business combinations , imputed finance charges and remeasurement 
adjustments on certain Other payables arising from intangible asset acquisitions,  legal settlements  and 
remeasurement adjustments relating to certain Other payables and debt items  assumed from the Alexion 
acquisition 
 
‒ The tax effects of the adjustments above are excluded from the Core Tax charge 
 
Details on the nature of Core financial measures are provided on page 61 of the Annual Report and Form 20-F 
Information 2023.  
 
Reference should be made to the Reconciliation of Reported to Core financial measures table included in the 
financial performance section in this announcement. 
 
Product Sales Gross Margin is calculated by dividing the difference between Product Sales and Cost of Sales 
by the Product Sales. The calculation of Reported and Core Product Sales Gross Margin excludes the impact 
of Alliance Revenue and Collaboration Revenue and any associated costs, thereby reflecting the underlying 
performance of Product Sales. 
 
EBITDA is defined as Reported Profit before tax after adding back Net finance expense, results from Joint 
ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made 
to the Reconciliation of Reported Profit before tax to EBITDA included in the financial performance section  in 
this announcement. 
 
Operating margin is defined as Operating profit as a percentage of Total Revenue. 
 
Net debt is defined as Interest -bearing loans and borrowings and Lease liabilities, net of Cash and cash 
equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 
'Net debt' included in the Notes to the Interim financial statements in this announcement.

===== SIDA 7 =====

7 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
The Company strongly encourages investors and analysts not to rely on any single financial measure, but to 
review AstraZeneca's financial statements, including the Notes thereto, and other available Company reports, 
carefully and in their entirety. 
 
Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to 
totals. 
 
Total Revenue 
 
Table 4: Total Revenue by therapy area and medicine7 
 
  9M 2024  Q3 2024  
    % Change    % Change  
   $m  % Total  Actual  CER  $m  % Total  Actual  CER  
Oncology   16,009  41  19  22  5,569  41  19  22  
- Tagrisso   4,877  12  11  15  1,674  12  14  17  
- Imfinzi  3,463  9  18  22  1,203  9  13  16  
- Calquence   2,321  6  26  27  813  6  24  25  
- Lynparza   2,228  6  8  10  778  6  11  13  
- Enhertu   1,442  4  57  60  510  4  50  55  
- Zoladex  845  2  17  24  278  2  12  18  
- Imjudo  208  1  30  32  72  1  20  22  
- Truqap  267  1  n/m  n/m  125  1  n/m  n/m  
- Orpathys   36  -  5  8  11  -  (11) (11) 
- Other Oncology  322  1  (18) (12) 106  1  (10) (5) 
BioPharmaceuticals: CVRM   9,379  24  18  21  3,159  23  18  20  
- Farxiga   5,779  15  32  34  1,943  14  25  27  
- Brilinta   992  3  -  1  327  2  (1) (1) 
- Crestor  894  2  4  9  304  2  10  14  
- Lokelma  392  1  31  34  143  1  40  42  
- Seloken/Toprol-XL   466  1  (6) (1) 151  1  (2) 1  
- roxadustat   261  1  23  26  95  1  26  25  
- Andexxa  159  -  24  26  54  -  36  38  
- Wainua  44  -  n/m  n/m  23  -  n/m  n/m  
- Other CVRM  392  1  (27) (26) 120  1  (22) (20) 
BioPharmaceuticals: R&I   5,750  15  22  24  1,959  14  26  29  
- Symbicort   2,195  6  19  22  705  5  27  31  
- Fasenra  1,218  3  7  8  436  3  12  13  
- Breztri  721  2  51  53  266  2  56  57  
- Pulmicort   517  1  5  9  138  1  (6) (4) 
- Tezspire  471  1  >2x  >2x  191  1  >2x  >2x  
- Saphnelo   327  1  71  72  124  1  63  64  
- Airsupra  41  -  n/m  n/m  21  -  n/m  n/m  
- Other R&I   259  1  (28) (27) 78  1  (32) (32) 
BioPharmaceuticals: V&I   811  2  (14) (12) 460  3  48  49  
- Beyfortus  319  1  >2x  >2x  238  2  73  72  
- Synagis   346  1  (10) (4) 93  1  (6) 3  
- COVID-19 mAbs  31  -  (90) (90) 28  -  >10x  >10x  
- FluMist  109  -  24  21  100  1  34  31  
- Other V&I  6  -  (79) (80) 0  -  (63) n/m  
Rare Disease  6,391  16  10  14  2,148  16  9  11  
- Ultomiris   2,835  7  32  35  1,031  8  33  35  
- Soliris  2,045  5  (16) (11) 606  4  (22) (18) 
- Strensiq   996  3  18  19  343  3  20  21  
- Koselugo   366  1  49  55  119  1  37  39  
- Kanuma   149  -  15  16  49  -  10  9  
 
7 The presentation of Table 4 has been updated to show Total Revenue by medicine, by including Alliance Revenue and Collaboration 
Revenue within each revenue figure. Previously, this table showed Product Sales for each medicine and therapy area, and the Company’s 
total Alliance Revenue and Collaboration Revenue were shown as separate lines at the bottom of the table.

===== SIDA 8 =====

8 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Other Medicines   843  2  (10) (4) 270  2  (12) (8) 
- Nexium   685  2  (8) (2) 216  2  (13) (8) 
- Others   157  -  (17) (15) 54  -  (7) (7) 
Total  39,182  100  16  19  13,565  100  18  21  
 
Table 5: Alliance Revenue 
 
  9M 2024 Q3 2024 
 
  % Change  % Change 
  $m  Actual  CER  $m  Actual  CER  
Enhertu  1,045  41  42  361  36  38  
Tezspire  303  69  69  123  65  65  
Beyfortus  75  >4x  >4x  49  >2x  >2x  
Other Alliance Revenue   75  11  11  26  29  29  
Total   1,498  49  50  559  48  50  
 
Table 6: Collaboration Revenue 
  9M 2024 Q3 2024 
 
  % Change  % Change 
  $m  Actual  CER  $m  Actual  CER  
Farxiga: sales milestones   52  87  87  3  12  14  
Beyfortus: sales milestones  56  (21) (23) 56  (21) (23) 
Total   108  (66) (66) 59  (39) (40) 
 
Table 7: Total Revenue by therapy area 
 
  9M 2024 Q3 2024 
 
   % Change   % Change 
  $m  % Total   Actual  CER  $m  % Total   Actual  CER  
Oncology  16,009  41  19  22  5,569  41  19  22  
Biopharmaceuticals 
 
15,940  41  17  20  5,578  41  23  25  
CVRM 
 
9,379  24  18  21  3,159  23  18  20  
R&I  5,750  15  22  24  1,959  14  26  29  
V&I 
 
811  2  (14) (12) 460  3  48  49  
Rare Disease 
 
6,391  16  10  14  2,148  16  9  11  
Other Medicines 
 
843  2  (10) (4) 270  2  (12) (8) 
Total 
 
39,182  100  16  19  13,565  100  18  21  
 
Table 8: Total Revenue by region 
 
  9M 2024  Q3 2024 
     % Change     % Change 
  $m  % Total   Actual  CER  $m  % Total   Actual  CER  
US  16,703  43  20  20  6,008  44  23  23  
Emerging Markets 
 
10,541  27  14  23  3,423  25  15  23  
China 
 
5,049  13  12  15  1,671  12  15  15  
Emerging Markets ex. China 
 
5,492  14  16  30  1,752  13  16  31  
Europe 
 
8,240  21  22  22  2,875  21  22  22  
Established ROW 
 
3,698  9  (4) 4  1,260  9  (1) 4  
Total 
 
39,182  100  16  19  13,565  100  18  21  
 
Oncology 
 
Oncology Total Revenue of $16,009m in 9M 2024 increased by 19% (22% at CER), representing 41% of overall 
Total Revenue (9M 2023: 40%).  
 
Tagrisso

===== SIDA 9 =====

9 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   4,877  1,996 1,365 956 560 
Actual change  11%  19% 8% 16% (10%) 
CER change   15%  19% 16% 16% (2%) 
 
Region   Drivers and commentary 
Worldwide   Strong global demand for Tagrisso in adjuvant (ADAURA) and 1st-line settings (FLAURA, 
FLAURA-2) 
US   Continued demand growth in both the adjuvant and metastatic settings, with some additional 
benefit coming from improved affordability  
Emerging Markets   Encouraging demand growth, partly offset by NRDL price reduction in prior year period 
Europe   Continued demand growth across adjuvant and metastatic settings  
Established RoW   Continued demand growth across adjuvant and metastatic settings with year-over-year 
comparison reflecting price reduction in Japan in June 2023 
 
Imfinzi 
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   3,463  1,883 365 695 520 
Actual change  18%  18% 37% 30% (3%) 
CER change   22%  18% 61% 29% 6% 
 
Region   Drivers and commentary 
Worldwide   Strong demand growth driven by BTC (TOPAZ-1), HCC (HIMALAYA), and increased patient 
share in Stage IV NSCLC (POSEIDON) and extensive-stage SCLC (CASPIAN) 
US   Continued demand growth driven primarily by HCC and extensive-stage SCLC, having 
achieved peak market share as established standard of care in BTC  
Emerging Markets   Strong demand growth driven across all approved indications, in particular BTC 
Europe   Growth driven by share gains in extensive-stage SCLC as well as new launches in HCC, 
BTC and NSCLC 
Established RoW   Increased demand in GI indications, with year-over-year comparison reflecting the 25% and 
11% mandatory price reductions in Japan effective from 1 February 2024 and 1 August 
2024 respectively 
 
Calquence 
 
9M 2024, $m  Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   2,321  1,617 116 489 99 
Actual change  26%  21% 68% 38% 23% 
CER change   27%  21% 90% 38% 27% 
 
Region   Drivers and commentary 
Worldwide   Sustained BTKi leadership in front-line CLL (ELEVATE-TN) 
US   Growth driven by leading share of new patient starts in front-line CLL, with some additional 
favourability coming from improved affordability 
Europe   Strong growth momentum in front-line CLL, maintaining share of 1L new patient starts in 
competitive environment  
 
Lynparza 
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   2,228  954 475 612 187 
Actual change  8%  6% 16% 13% (13%) 
CER change   10%  6% 25% 12% (7%) 
 
Region   Drivers and commentary

===== SIDA 10 =====

10 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Worldwide   Lynparza remains the leading medicine in the PARP inhibitor class globally across four tumour 
types (ovarian, breast, prostate, pancreatic), as measured by total prescription volume 
 No Collaboration Revenue for Lynparza was recognised in either 9M 2024 or 9M 2023 
US   Continued leadership within competitive PARP inhibitor class, with demand growth across 
all indications 
Emerging Markets   Volume growth in China from increased share following inclusion of HRD-positive ovarian 
cancer (PAOLA-1) on NRDL with no price reduction 
Europe   Growth driven by increased market share and additional launches in early breast cancer 
(OlympiA) and metastatic prostate cancer (PROpel)  
Established RoW   PARP class leadership maintained with year-over-year comparison reflecting 7.7% price 
reduction in Japan in November 2023   
 
 
Enhertu 
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   1,442  642 353 400 47 
Actual change  57%  24% 97% 95% >2x  
CER change   60%  24% >2x  95% >2x  
 
Region   Drivers and commentary 
Worldwide   Established standard of care in HER2-positive (DESTINY-Breast03) and HER2-low 
(DESTINY-Breast04) metastatic breast cancer 
 Encouraging early uptake, particularly in gynaecological indications following tumour-
agnostic approval in April 2024 (DESTINY-PanTumor02, DESTINY-Lung01, 
DESTINY-CRC02) 
 Combined sales of Enhertu, recorded by Daiichi Sankyo and AstraZeneca, amounted to 
$2,729m in 9M 2024 (9M 2023: $1,844m) 
US   US in-market sales, recorded by Daiichi Sankyo, amounted to $1,342m in 9M 2024 
(9M 2023: $1,087m)  
Emerging Markets   Increased demand growth following commercial breast cancer launch in China in Q1 2024 
Europe   Continued demand growth due to increasing adoption in HER2-positive and HER2-low 
metastatic breast cancer 
Established RoW   AstraZeneca's Alliance Revenue includes a mid single-digit percentage royalty on Daiichi 
Sankyo's sales in Japan  
 
Other Oncology medicines 
 
 9M 2024 Change  
Total Revenue  $m Actual CER Drivers and commentary 
Zoladex  845 17% 24%  Strong underlying growth in China and Emerging Markets and 
moderate growth in Europe with reduced uptake in Japan 
Imjudo  208 30% 32%  Continued growth across markets 
Truqap  267 n/m n/m  Strong demand growth with strong uptake in biomarker altered 
subgroup of HR-positive HER2-negative metastatic breast cancer 
(CAPItello-291) 
Orpathys  36 5% 8%  Demand in China for the treatment of patients with NSCLC with 
MET exon 14 skipping alterations 
Other Oncology  322 (18%) (12%)  Decline in Faslodex Total Revenue due to VBP implementation in 
China in March 2024 and generic erosion in Europe 
 
 
BioPharmaceuticals 
 
BioPharmaceuticals Total Revenue increased by 17% (20% at CER) in 9M 2024 to $15,940m, representing 
41% of overall Total Revenue (9M 2023: 40%). 
 
BioPharmaceuticals - CVRM

===== SIDA 11 =====

11 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
CVRM Total Revenue increased by 18% (21% at CER) to $9,379m in 9M 2024 and represented 24% of overall 
Total Revenue (9M 2023: 23%). 
 
Farxiga 
 
9M 2024, $m  Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue  5,779  1,280 2,225 1,903 371 
Actual change  32%  28% 34% 40% (2%) 
CER change   34%  28% 41% 39% 5% 
 
Region   Drivers and commentary 
Worldwide 
 
  Farxiga volume continued to grow faster than the overall SGLT2 market in all major regions, 
driven by continued demand in heart failure and CKD 
 SGLT2 class growth underpinned by updated cardiorenal guidelines 
US   Growth driven by underlying demand in HFrEF and CKD 
 Launch of an authorised generic in the first quarter of 2024 
Emerging Markets 
 
  Increased reimbursement supporting solid growth despite entry of generic competition in 
some markets 
Europe   Continued strong class growth and market share gains 
Established RoW   Continued demand growth partially offset by generic competition in Canada 
 In Japan, AstraZeneca sells to collaborator Ono Pharmaceutical Co., Ltd, which records in-
market sales 
 
Other CVRM medicines 
 
 9M 2024 Change  
Total Revenue  $m Actual CER Drivers and commentary 
Brilinta  992 - 1%  Continued sales growth in Emerging Markets, decline in Est. RoW 
driven by generic competition in Canada 
Crestor  894 4% 9%  Continued sales growth in Emerging Markets 
Seloken  466 (6%) (1%)  Growth in ex-China EM markets offsetting declines in other regions 
Lokelma  392 31% 34%  Strong growth in all major regions, particularly in Europe and 
Emerging Markets. Continued launches in new markets 
Roxadustat  261 23% 26%  Continued patient and volume growth 
Andexxa  159 24% 26%  Demand growth 
Wainua  44 n/m n/m  Encouraging launch uptake following ATTRv-PN approval in the 
US in December 2023 
Other CVRM  392 (27%) (26%)  Generic competition  
 
BioPharmaceuticals - R&I  
 
Total Revenue of $5,750m from R&I medicines increased 22% (24% at CER) and represented 15% of overall 
Total Revenue (9M 2023: 14%).  
 
Fasenra 
 
9M 2024, $m  Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   1,218  750 68 294 106 
Actual change  7%  4% 43% 12% (1%) 
CER change   8%  4% 52% 11% 6% 
  
Region   Drivers and commentary 
Worldwide   Continued severe asthma market share leadership in IL-5 class across major markets 
US   Sustained double-digit volume growth 
Emerging Markets   Continued strong demand growth driven by launch acceleration across key markets  
Europe   Sustained leadership in severe eosinophilic asthma

===== SIDA 12 =====

12 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Established RoW   In Japan, maintained class leadership in a broadly stable market 
 
Breztri 
 
9M 2024, $m  Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   721  367 199 102 53 
Actual change  51%  40% 62% 86% 42% 
CER change   53%  40% 68% 85% 51% 
 
Region   Drivers and commentary 
Worldwide   Fastest growing single-inhaler triple medicine within the expanding FDC triple class 
US   Consistent share growth within the expanding FDC triple class  
Emerging Markets   Maintained market share leadership in China with strong FDC triple class penetration 
 Further expansion with launches in additional geographies 
Europe   Sustained growth across markets driven by new launches  
Established RoW   Increased market share in Japan  
 
Tezspire 
 
9M 2024, $m  Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   471  303 8 105 55 
Actual change  >2x   70% n/m >3x  >2x  
CER change   >2x   70% n/m >3x  >2x  
 
Region   Drivers and commentary 
Worldwide   Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $843m in 
9M 2024 (9M 2023: $438m) 
US    Continued growth in total prescriptions, with majority of patients new-to-biologics 
Europe    Achieved and maintained new-to-brand leadership across multiple markets, new launches 
continue to progress  
Established RoW   Sustained market share growth in Japan and other major geographies, with continued 
launches 
 
Symbicort 
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   2,195  887 653 415 240 
Actual change  19%  51% 9% 2% (2%) 
CER change   22%  51% 19% 1% - 
 
Region   Drivers and commentary 
Worldwide   Symbicort remained the global market leader within a stable ICS/LABA class 
US   Continued strong demand for the authorised generic, limitation of patient out-of-pocket 
expenses and favourable channel mix 
Emerging Markets   Sustained demand growth across markets 
Europe    Continued growth in some markets within mild asthma partially offset generic erosion and a 
slowing overall market 
Established RoW   Continued generic erosion in Japan  
 
Other R&I medicines 
 
 9M 2024    Change  
Total Revenue  $m Actual CER Drivers and commentary 
Saphnelo  327 71% 72%  Demand acceleration in the US, and additional growth driven by 
ongoing launches in Europe and Established RoW

===== SIDA 13 =====

13 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Airsupra  41 n/m n/m  Strong US launch momentum and volume uptake. Revenue in the 
period reflects introductory discounts as early access continues to 
build 
Pulmicort  517 5% 9%  >80% of revenues from Emerging Markets  
Other R&I  259 (28%) (27%)  Continued generic competition 
 
BioPharmaceuticals - V&I  
 
Total Revenue from V&I medicines reduced by 14% (12% at CER) to $811m (9M 2023: $944m) and represented 
2% of overall Total Revenue (9M 2023: 3%).  
 
V&I medicines 
 
 9M 2024 Change  
Total Revenue  $m Actual CER Drivers and commentary 
Beyfortus  319 >2x  >2x   Growth driven increasing demand and expanded production 
capacity  
 Product Sales recognises AstraZeneca's sales of manufactured 
Beyfortus product to Sanofi  
 Alliance Revenue recognises AstraZeneca's 50% share of gross 
profits on sales of Beyfortus in major markets outside the US, and 
25% of brand revenues in rest of world markets 
 AstraZeneca has no participation in US profits or losses 
Synagis  346 (10%) (4%)  As anticipated, Synagis demand decreased following rapid 
adoption of Beyfortus 
COVID-19 mAbs  31 (90%) (90%)  Decline in Evusheld sales and Collaboration Revenue (Total 
Revenue 9M 2023: $306m) 
FluMist  109 24% 21%  Demand growth across key markets in particular Europe and 
benefit from earlier start in flu season in Q3 2024 compared to prior 
year 
Other V&I  6 (79%) (80%)  Decline in Vaxzevria sales (9M 2023: $28m) 
 
Rare Disease 
 
Total Revenue from Rare Disease medicines increased by 10% (14% at CER) in 9M 2024 to $6,391m, 
representing 16% of overall Total Revenue (9M 2023: 17%). 
 
Ultomiris 
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   2,835  1,629 92 649 465 
Actual change  32%  29% 97% 31% 37% 
CER change  35%  29% >2x  30% 50% 
 
Region   Drivers and commentary 
Worldwide   Growth due to increased use in neurology, geographic expansion, further patient demand 
and conversion from Soliris 
 Ultomiris Total Revenue includes sales of Voydeya, which is approved as an add-on 
treatment to Ultomiris and Soliris for the 10-20% of PNH patients who experience clinically 
significant EVH 
US   Strong growth in patient demand in gMG (CHAMPION-MG) and NMOSD (CHAMPION-
NMOSD), both new to branded medicines, as well as continued conversion from Soliris  
Emerging Markets   Expansion into new markets and growth in patient demand 
Europe   Strong demand growth following recent launches, particularly from neurology indications, 
accelerated conversion from Soliris, partially offset by price reductions to secure 
reimbursement for new indications 
Established RoW   Continued conversion from Soliris and strong demand following new launches

===== SIDA 14 =====

14 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 
Soliris  
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   2,045  1,170 365 346 164 
Actual change  (16%)  (11%) 8% (35%) (34%) 
CER change  (11%)  (11%) 39% (35%) (31%) 
 
Region   Drivers and commentary 
US   Decline driven by successful conversion of Soliris patients to Ultomiris  
Emerging Markets   Growth driven by patient demand  
Europe   Decline driven by biosimilar erosion in PNH and aHUS and successful conversion from 
Soliris to Ultomiris 
Established RoW   Decline driven by successful conversion from Soliris to Ultomiris 
 
Strensiq 
 
9M 2024, $m   Worldwide  US Emerging Markets Europe Established RoW 
Total Revenue   996  815 39 73 69 
Actual change  18%  18% 34% 15% 8% 
CER change  19%  18% 48% 14% 18% 
 
Region   Drivers and commentary 
Worldwide   Growth driven by strong patient demand 
 
Other Rare Disease medicines 
 
 9M 2024 Change  
Total Revenue  $m Actual CER Drivers and commentary 
Koselugo  366 49% 55%  Driven by patient demand and expansion in new markets 
Kanuma  149 15% 16%  Continued global demand  
 
Other medicines (outside the main therapy areas) 
 
 9M 2024 Change  
Total Revenue  $m Actual CER Drivers and commentary 
Nexium  685 (8%) (2%)  Stable in Emerging Markets, which now accounts for two-thirds of 
Nexium revenue, offset by generic erosion in other markets 
Others  157 (17%) (15%)  Continued impact of generic competition 
 
Financial performance 
 
Table 9: Reported Profit and Loss 
 
  9M 2024 9M 2023 % Change  Q3 2024 Q3 2023 % Change 
  $m   $m   Actual   CER   $m  $m  Actual   CER   
Total Revenue  39,182  33,787  16  19  13,565  11,492  18  21   
- Product Sales  37,576  32,466  16  19  12,947  11,018  18  20   
- Alliance Revenue  1,498  1,004  49  50  559  377  48  50   
- Collaboration Revenue  108  317  (66) (66) 59  97  (39) (40) 
Cost of sales  (7,482) (5,960) 26  28  (3,081) (2,095) 47  48   
Gross profit  31,700  27,827  14  17  10,484  9,397  12  15   
Distribution expense  (412) (394) 4  7  (145) (129) 12  15   
R&D expense  (8,906) (7,862) 13  14  (3,115) (2,584) 21  21   
SG&A expense  (14,567) (13,845) 5  7  (5,143) (4,800) 7  8

===== SIDA 15 =====

15 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Other operating income & 
expense 
 152  1,233  (88) (88) 25  70  (65) (61) 
Operating profit  7,967  6,959  14  23  2,106  1,954  8  18  
Net finance expense  (919) (945) (3) (7) (274) (291) (6) (15) 
Joint ventures and associates  (23) (12) n/m 97  (4) (11) (53) (54) 
Profit before tax  7,025  6,002  17  28  1,828  1,652  11  24  
Taxation  (1,484) (1,000) 48  62  (395) (274) 44  62  
Tax rate  21%  17%    22%  17%    
Profit after tax  5,541  5,002  11  21  1,433  1,378  4  17  
Earnings per share  $3.57  $3.22  11  21  $0.92  $0.89  4  17  
 
Table 10: Reconciliation of Reported Profit before tax to EBITDA 
 
  9M 2024 9M 2023 % Change Q3 2024 Q3 2023 % Change 
  $m  $m   Actual  CER  $m  $m  Actual  CER  
Reported Profit before tax   7,025  6,002  17  28  1,828  1,652  11   24  
Net finance expense   919  945  (3) (7) 274  291  (6) (15) 
Joint ventures and associates   23  12  n/m 97  4  11  (53) (54) 
Depreciation, amortisation and 
impairment  
 4,351  4,060  7  7  1,817  1,282  41   41  
EBITDA   12,318  11,019  12  17  3,923  3,236  21  27  
 
Table 11: Reconciliation of Reported to Core financial measures: 9M 20248 
 
9M 2024 
 
Reported Restructuring 
Intangible 
Asset 
Amortisation & 
Impairments 
Other Core Core 
% Change 
  $m  $m  $m  $m  $m  Actual  CER  
Gross profit  31,700  655  24  4  32,383  15  19  
Product Sales 
Gross Margin  80%     82%  -  -  
Distribution 
expense 
 (412) -  -  -  (412) 4  7  
R&D expense  (8,906) 221  38  9  (8,638) 17  18  
% of Total Revenue  23%     22%  -  -  
SG&A expense  (14,567) 180  3,343  291  (10,753) 11  13  
% of Total Revenue  37%     27%  +1pp  +1pp  
Total operating 
expense 
 (23,885) 401  3,381  300  (19,803) 13  15  
Other operating 
income & expense 
 152  (2) -  (1) 149  (87) (87) 
Operating profit  7,967  1,054  3,405  303  12,729  8  13  
Operating Margin  20%        32%  -2pp  -2pp  
Net finance 
expense 
 (919) -  -  60  (859) 18  13  
Taxation  (1,484) (189) (621) (67) (2,361) 15  22  
EPS  $3.57  $0.56  $1.80  $0.19  $6.12  5  11  
 
Table 12: Reconciliation of Reported to Core financial measures: Q3 20248 
Q3 2024 
 
Reported Restructuring 
Intangible 
Asset 
Amortisation & 
Impairments 
Other Core Core 
% Change 
 
8 The presentation of this table has been updated by removing the "Acquisition of Alexion" column due to immateriality of items in this 
category

===== SIDA 16 =====

16 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
  $m  $m  $m  $m  $m  Actual  CER  
Gross profit  10,484  619  8  1  11,112  18  21  
Product Sales 
Gross Margin  76%     81%  -  -  
Distribution 
expense 
 (145) -  -  -  (145) 12  15  
R&D expense  (3,115) 44  1  2  (3,068) 23  24  
% of Total Revenue  23%     23%  -1pp  -1pp  
SG&A expense  (5,143) 42  1,460  36  (3,605) 8  9  
% of Total Revenue  38%     27%  +3pp  +3pp  
Total operating 
expense 
 (8,403) 86  1,461  38  (6,818) 14  16  
Other operating 
income & expense 
 25  -  -  (1) 24  (65) (61) 
Operating profit  2,106  705  1,469  38  4,318  22  27  
Operating Margin  16%        32%  +1pp  +2pp  
Net finance 
expense 
 (274) -  -  (55) (329) 46  35  
Taxation  (395) (109) (254) 5  (753) 21  28  
EPS  $0.92  $0.38  $0.78  -  $2.08  20  27  
 
Profit and Loss drivers 
 
Gross profit  
 
‒ The calculation of Reported and Core Product Sales Gross Margin excludes the impact of Alliance Revenue 
and Collaboration Revenue 
 
‒ The change in Product Sales Gross Margin (Reported and Core) in 9M 2024 was impacted by: 
 
‒ Positive effects from product mix. The increased contribution from Rare Disease and Oncology medicines 
had a positive impact on the Product Sales Gross Margin  
 
‒ Dilutive effects from product mix. The rising contribution of Product Sales with profit sharing arrangements 
(Lynparza, Enhertu, Tezspire, Koselugo) has a negative impact on Product Sales Gross Margin because 
AstraZeneca records Product Sales in certain markets and pays away a share of the gross profits to its 
collaboration partners. The growth in Beyfortus also has a dilutive impact on Product Sales Gross Margin, 
as AstraZeneca is responsible for manufacturing, and Sanofi is responsible for distribution. AstraZeneca 
records its sales to Sanofi as Product Sales , and those sales  generate a lower Product Sales Gross 
Margin than the Company average  
 
‒ Dilutive effects from geographic mix. In Emerging Markets, the Product Sales Gross Margin tends to be 
below the Company average  
 
‒ The reported Product Sales Gross Margin included inventory and related contract provisions of $638m 
recorded in the third quarter related to Andexxa, which was part of the PAAG R restructuring program 
(see Note 2 in the Notes to the interim financial statements section) 
 
‒ Variations in Product Sales Gross Margin performance between periods can continue to be expected due to 
product seasonality, foreign exchange fluctuations, and other effects 
 
R&D expense 
 
‒ The change in R&D expense (Reported and Core) in the period was impacted by: 
 
‒ Positive data read-outs for several high priority medicines that have ungated late-stage trials 
 
‒ Investment in platforms, new technology and capabilities to enhance R&D capabilities 
 
‒ Addition of R&D projects following completion of previously announced business development activity 
including Icosavax, Gracell, Fusion and Amolyt  
 
‒ The change in Reported R&D expense was also impacted by intangible asset impairments in the prior period

===== SIDA 17 =====

17 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
SG&A expense 
 
‒ The change in SG&A expense (Reported and Core ) in the period was driven primarily by market 
development activities for launches and to support continued growth in existing brands 
 
‒ The Reported SG&A expense included impairment charges in the third quarter of $504m recorded against 
the Andexxa intangible asset  
 
Other operating income and expense 
 
‒ In the prior year period, Other operating income and expense included a $241m gain on the disposal of the 
US rights to Pulmicort Flexhaler and a $712m gain relating to contractual arrangements for Beyfortus 
 
Net finance expense 
 
‒ Core Net finance expense increased 18% (13% increase at CER) due to the increased level of debt and new 
debt issued at higher interest rates 
 
Taxation 
 
‒ The effective Reported Tax rate for the nine months to 30 September 2024 was 21% (9M 2023: 17%) and 
the effective Core Tax rate was 20% (9M 2023: 19%) 
 
‒ The cash tax paid for the nine months to 30 September 2024  was $1,978m (9M 2023 : $1,710m), 
representing 28% of Reported Profit before tax (9M 2023: 26%) 
 
Table 13: Cash Flow summary 
 
  9M 2024  9M 2023  Change  
  $m  $m  $m  
Reported Operating profit   7,967  6,959  1,008  
Depreciation, amortisation and impairment   4,351  4,060  291  
Movement in working capital and short-term provisions   (543) 150  (693) 
Gains on disposal of intangible assets   (34) (247) 213  
Fair value movements on contingent consideration arising from 
business combinations  
 251  202  49  
Non-cash and other movements   15  (623) 638  
Interest paid   (1,075) (826) (249) 
Taxation paid   (1,978) (1,710) (268) 
Net cash inflow from operating activities   8,954  7,965  989  
Net cash inflow before financing activities   2,155  4,978  (2,823) 
Net cash inflow/(outflow) from financing activities   (3,325) (6,276) 2,951  
 
The change in Net cash inflow before financing activities of $2,823m is primarily driven by Acquisitions of 
subsidiaries, net of cash acquired of $2,771m, and relates to the acquisition of Gracell Biotechnologies, Inc. for 
$774m and acquisition of Fusion Pharmaceuticals Inc., for $1,997m as compared to the acquisition of Neogene 
Therapeutics, Inc. for $189m in 9M 2023.  
 
The decrease in Net cash outflow from financing activities of $2,951m is primarily driven by increased issuance 
of long-term loans of $6,492m in the period compared to $3,816m issued in the comparative period . 
 
Capital expenditure 
 
Capital expenditure amounted to $1,216m in 9M 2024 (9M 2023: $836m). The increase of capital expenditure 
in 2024 is driven by investment in several major manufacturing projects and continued investment in technology 
upgrades. 
 
Table 14: Net debt summary 
 
 At 30  
 Sep 2024 
At 31  
 Dec 2023 
At 30  
Sep 2023 
 $m  $m  $m  
Cash and cash equivalents 4,797  5,840  4,871  
Other investments 133  122  244  
Cash and investments 4,930  5,962  5,115

===== SIDA 18 =====

18 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 At 30  
 Sep 2024 
At 31  
 Dec 2023 
At 30  
Sep 2023 
 $m  $m  $m  
Overdrafts and short-term borrowings (769) (515) (515) 
Commercial paper (472) -  -  
Lease liabilities (1,422) (1,128) (979) 
Current instalments of loans (12) (4,614) (4,857) 
Non-current instalments of loans (28,887) (22,365) (22,225) 
Interest-bearing loans and borrowings (Gross debt) (31,562) (28,622) (28,576) 
Net derivatives 284  150  90  
Net debt (26,348) (22,510) (23,371) 
 
 
Net debt increased by $3,838m in the nine months to 30 September 2024 to $26,348m. Details of the committed 
undrawn bank facilities are disclosed within the going concern section of Note 1. Details of the Company 's 
solicited credit ratings and further details on Net debt are disclosed in Note 3. 
 
Capital allocation 
 
The Company's capital allocation priorities include: investing in the business and pipeline; maintaining a strong, 
investment-grade credit rating; potential value-enhancing business development opportunities; and supporting 
the progressive dividend policy . As announced at the Annual General Meeting on 11 April 2024, the total 
dividend for FY 2024 will increase by $0.20 per share to $3.10 per share.  
 
In approving the declaration of dividends, the Board considers both the liquidity of the company and the level of 
reserves legally available for distribution. Dividends are paid to shareholders from AstraZeneca PLC, a Group 
holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions is 
dependent on the creation of profits for distribution and the receipt of funds from subsidiary companies. The 
consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect 
the profit available for distribution to the shareholders of AstraZeneca PLC.  
 
Summarised financial information for guarantee of securities of subsidiaries  
 
AstraZeneca Finance LLC ( "AstraZeneca Finance") is the issuer of 1.2% Notes due 2026, 4.8% Notes due 
2027, 4.875% Notes due 2028, 1.75% Notes due 2028, 4.85% Notes due 2029, 4.9% Notes due 2030, 4.9% 
Notes due 2031, 2.25% Notes due 2031, 4.875% Notes due 2033, 5% Notes due 2034, 3.121% EUR Notes 
due 2030 and 3.278% EUR Notes due 2033 (the "AstraZeneca Finance Notes "). Each series of AstraZeneca 
Finance Notes has been fully and unconditionally guaranteed by AstraZeneca PLC. AstraZeneca Finance is 
100% owned by AstraZeneca PLC and each of the guarantees issued by AstraZeneca PLC is full and 
unconditional and joint and several. 
 
The AstraZeneca Finance Notes are senior unsecured obligations of AstraZeneca Finance and rank equally 
with all of AstraZeneca Finance's existing and future senior unsecured and unsubordinated indebtedness. The 
guarantee by AstraZeneca PLC of the AstraZeneca Finance Notes is the senior unsecured obligation of 
AstraZeneca PLC and ranks equally with all of AstraZeneca PLC 's existing and future senior unsecured and 
unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured 
indebtedness of AstraZeneca PLC to the extent of the value of the assets securing such indebtedness. The 
AstraZeneca Finance Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries 
of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance Notes.  
 
AstraZeneca PLC manages substantially all of its operations through divisions, branches and/or investments in 
subsidiaries and affiliates. Accordingly, the ability of AstraZeneca PLC to service its debt and guarantee 
obligations is also dependent upon the earnings of its subsidiaries, affiliates, branches and divisions, whether 
by dividends, distributions, loans or otherwise.  
 
Please refer to the Consolidated financial statements of AstraZeneca PLC in our Annual Report on Form 20 -F 
as filed with the SEC and information contained herein for further financial information regarding AstraZeneca 
PLC and its consolidated subsidiaries. For further details, terms and conditions of the AstraZeneca Finance 
Notes please refer to AstraZeneca PLC 's reports on Form 6 -K furnished to the SEC on 30 July 2024,  22 
February 2024, 3 March 2023 and 28 May 2021.

===== SIDA 19 =====

19 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Pursuant to Rule 13 -01 and Rule 3 -10 of Regulation S -X under the Securities Act of 1933, as amended (the 
"Securities Act "), we present below the summary financial information for AstraZeneca PLC, as Guarantor, 
excluding its consolidated subsidiaries, and AstraZeneca Finance, as the issuer, excluding its consolidated 
subsidiaries. The following summary financial information o f AstraZeneca PLC and AstraZeneca Finance is 
presented on a combined basis and transactions between the combining entities have been el iminated. 
Financial information for non -guarantor entities has been excluded. Intercompany balances and transactions 
between the obligor group and the non-obligor subsidiaries are presented on separate lines. 
 
Table 15: Obligor group summarised Statement of comprehensive income 
 
  9M 2024 9M 2023 
  $m  $m  
Total Revenue  -  -  
Gross profit  -  -  
Operating loss  -  (2) 
Loss for the period  (894) (695) 
Transactions with subsidiaries that are not issuers or guarantors  1,342  9,758  
 
Table 16: Obligor group summarised Statement of financial position  
 
  At 30 Sep 2024  At 30 Sep 2023  
  $m  $m  
Current assets  10  6  
Non-current assets  84  -  
Current liabilities  (801) (4,760) 
Non-current liabilities  (28,906) (22,077) 
Amounts due from subsidiaries that are not issuers or guarantors  16,705  12,921  
Amounts due to subsidiaries that are not issuers or guarantors  -  (295) 
 
Foreign exchange 
 
The Company's transactional currency exposures on working capital balances, which typically extend for up to 
three months, are hedged where practicable using forward foreign  exchange contracts against the individual 
companies' reporting currency. Foreign  exchange gains and losses on forward contracts transacted for 
transactional hedging are taken to profit or to Other comprehensive income if the contract is in a designated 
cashflow hedge. In addition, the Company's external dividend payments, paid principally in pound sterling and 
Swedish krona, are fully hedged from announcement to payment date. 
 
Table 17: Currency sensitivities 
 
The Company provides the following information on currency-sensitivity: 
 
  
  Average 
rates vs. USD  
Annual impact ($m) of 
5% strengthening 
(FY 2024 average rate 
vs. FY 2023 average) 9 
Currency Primary Relevance  FY      
202310 
YTD     
202411 
Change 
 (%) 
Sep   
 202412 
Change 
 (%) 
 Total 
Revenue 
Core 
Operating 
Profit 
EUR Total Revenue  0.92  0.92  0  0.90  3   397 179  
CNY Total Revenue  7.09  7.21  (2) 7.08  0   322 182  
JPY Total Revenue  140.60  151.23  (7) 143.04  (2)  177 119  
Other13         453 227  
GBP Operating expense  0.80  0.78  3  0.76  6   60 (126) 
 
9 Based on best prevailing assumptions around currency profiles. 
10 Based on average daily spot rates 1 Jan 2023 to 31 Dec 2023. 
11 Based on average daily spot rates 1 Jan 2024 to 30 Sep 2024. 
12 Based on average daily spot rates 1 Sep 2024 to 30 Sep 2024. 
13 Other currencies include AUD, BRL, CAD, KRW and RUB.

===== SIDA 20 =====

20 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
  
  Average 
rates vs. USD  
Annual impact ($m) of 
5% strengthening 
(FY 2024 average rate 
vs. FY 2023 average) 9 
Currency Primary Relevance  FY      
202310 
YTD     
202411 
Change 
 (%) 
Sep   
 202412 
Change 
 (%) 
 Total 
Revenue 
Core 
Operating 
Profit 
SEK Operating expense  10.61  10.50  1  10.23  4   9 (63) 
 
Sustainability 
 
In September, AstraZeneca had a significant presence at Climate Week NYC and the 79th Session of the UN 
General Assembly in New York, with a delegation led by Pam Cheng, Executive Vice President of Global 
Operations and IT and Chief Sustainability Officer and  the company's US leadership. A programme of more 
than 50 engagements with governments, media, NGOs and the private sector focused on the interconnected 
issues of the climate crisis, health equity and health system resilience and the Company 's commitment t o 
contribute to more sustainable, resilient and equitable health systems.  
 
Related communications included an opinion piece published by the World Economic Forum (WEF) on how 
pharmaceutical companies are investing in nature to improve human and planetary health and an article in 
Foreign Policy on building sustainable health systems to manage the burden of non-communicable diseases. 
 
Access to healthcare 
 
‒ By end of August 2024, the Company's flagship Healthy Heart Africa programme had conducted more than 
61 million blood pressure screenings, identifying over 12.1 million people with elevated blood pressure and 
diagnosing over 4.87 million with high blood pressure     
 
‒ In October, the Company convened the  inaugural meeting of its Global Health Equity Advisory Board 
(HEAB), a group of 15 external stakeholders with representation from 11 countries and across disease areas, 
to advise on the Company's approach to help improve equitable health outcomes globally  
 
‒ AstraZeneca Chair Michel Demaré and Executive Vice President, Vaccines and Immune Therapies, Iskra 
Reic shared perspectives on health systems resilience in Health: A Political Choice - Building Resilience and 
Trust, a publication launched during the World Health Summit in collaboration with the World Health 
Organization 
 
‒ During the quarter,  the Partnership for Health System Sustainability and Resilience (PHSSR) initiative 
convened an Expert Advisory Group on the role of EU institutions in supporting sustainable healthcare 
financing of Member States. The PHSSR was also active in a session at the European Health Forum Gastein 
in collaboration with AstraZeneca, on the importance of decarbonising care pathways for the health of people 
and the planet. The session emphasised the need for early, targeted and patient-centred interventions within 
integrated EU and national public policy strategies 
 
‒ In September, through the Young Health Programme (YHP), 24 young health leaders from around the world 
received a Fellowship to attend the One Young World Summit in Montréal, Canada to support their focus on 
building a healthier and more equitable future. Additionally, in August, the YHP awarded scholarships to 
seven young global leaders  who are tackling the health impacts of the climate crisis to join a Climate 
Entrepreneurship Academy in New York.  During the quarter, YHP won Corporate Social Responsibilit y 
Programme of the Year at the Pharma Industry UK Awards 
 
Environmental protection 
 
‒ The Company reached a key sustainability milestone in its Ambition Zero Carbon decarbonisation strategy, 
with over 50% of its global vehicle fleet now fully electric, including in Europe, Japan and the US. 
AstraZeneca currently has over 10,000 battery electric vehicles (BEVs), with fully electric fleets in the 
Netherlands, Greece and Georgia 
 
‒ AstraZeneca's manufacturing site in Södertälje, Sweden - the Company's largest manufacturing site globally 
- has reduced its Scope 1 and 2 greenhouse (GHG) gas emissions by 98% since 2015, making it the 
Company's sixth site to have achieved this goal ahead of schedule. With this milestone, all locations in 
Sweden, including the strategic R&D Centre in Gothenburg, have now achieved their Scope 1 and 2 Ambition 
Zero Carbon Targets

===== SIDA 21 =====

21 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 
‒ Through the Sustainable Markets Initiative Health Systems Task Force, chaired by CEO Pascal Soriot, the 
Company contributed to the launch of the European Network on Climate and Health Education which took 
place at the World Health Summit in Berlin. The network brings together 25 leading universities from across 
Europe which are committed to training 10,000 medical students with skills to address the health impacts of 
climate change and deliver sustainable healthcare 
 
‒ The Company received the  Net Zero: Operations Transformation award at the 2024 Reuters Sustainability 
Awards in October, recognising its commitment to drive deep decarbonisation across its operations and fleet 
through the Ambition Zero Carbon strategy. The WEF also recognised two of the Company 's advanced 
manufacturing sites in Wuxi (China) and Södertälje (Sweden) as Fourth Industrial Revolution (4IR) 
Lighthouses, part of its Global Lighthouse Network which spotlights organisations harnessing advanced 
technologies such as digital and AI to drive next -generation operational excellence, environmental 
sustainability and workforce development 
 
‒ In August, the Company was recognised with awards by  My Green Lab  and the International Institute for 
Sustainable Laboratories  - the 2024 Freezer Challenge Winning Streak Award for Biotech & 
Pharmaceuticals, for being at the top of the sector and surpassing 2023 energy savings, and the Top Small 
Lab Award - Pharmaceutical and Biotech Sector - awarded to AZ Gothenburg Regional HBS Centre 
 
‒ The Company completed studies to support the first regulatory filings for the transition of  Breztri/Trixeo 
Aerosphere to an innovative, next -generation propellant with 99.9% lower Global Warming Potential than 
propellants used in currently available inhaled medicines. Reducing the carbon impact of pressurised -
metered dose inhalers is a key product -related element of Astr aZeneca's Ambition Zero Carbon strategy, 
alongside the Company's commitment to improving patient outcomes 
 
Ethics and transparency 
 
‒ In September, AstraZeneca was included in the TIME World's Best Companies 2024,  ranking first among 
pharmaceutical companies for sustainability transparency and in the top 70 out of 1,000 overall  
 
‒ In Mexico, AstraZeneca was third in the Great Place to Work (GPTW) ranking and the Company 's 
Guadalajara Global Innovation & Technology Centre was number one in the GPTW Western Region for 
companies with >500-5,000 employees for the fourth year in a row  
 
‒ AstraZeneca and 33 other partner organisations announced the launch of the VICT3R project, a public -
private partnership that aims to reduce the number of animals used in experimental studies through Virtual 
Control Groups (VCGs) created using cutting edge statistical and artificial intelligence (AI) techniques. The 
project aims to transform drug and chemical safety evaluation while promoting ethical research practices 
and environmental sustainability 
 
Research and development 
 
This section covers R&D events and milestones that have occurred since the prior results announcement on 
25 July 2024, up to and including events on 11 November 2024. 
 
A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical 
Trials Appendix, available on www.astrazeneca.com/investor-relations. The Clinical Trials Appendix includes 
tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entities in the 
pipeline.  
 
Oncology 
 
AstraZeneca presented new data across its diverse portfolio of cancer medicines at two major medical  
congresses since the prior results announcement: the IASLC 2024 World Conference on Lung Cancer (WCLC) 
hosted by the International Association for the Study of Lung Cancer and the 2024 European Society for Medical 
Oncology (ESMO) Congress . Across the two meetings, more than 130 abstracts were presented featuring 17 
approved and potential new medicines including five Presidential Symposia and 41 oral presentations. 
 
Tagrisso 
 
Event   Commentary

===== SIDA 22 =====

22 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Approval US  For the treatment of adult patients with unresectable, Stage III EGFRm NSCLC 
whose disease has not progressed during or following concurrent or sequential 
platinum-based chemoradiation therapy. (LAURA, September 2024) 
Phase II 
registrational 
trial readout 
SAVANNAH  Tagrisso plus Orpathys demonstrated a high, clinically meaningful and durable 
objective response rate  for patients with EGFRm NSCLC with high levels of 
mesenchymal epithelial transition factor (MET) overexpression and/or 
amplification, defined as IHC90+ and/or FISH10+, whose disease progressed on 
treatment with Tagrisso. (October 2024) 
 
Imfinzi and Imjudo 
 
Event   Commentary 
Approval Europe  Imfinzi plus chemotherapy followed by Imfinzi alone has been approved for patients 
with mismatch repair deficient disease. (DUO-E, August 2024) 
Approval Europe  Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi 
for patients with mismatch repair proficient disease. (DUO-E, August 2024) 
Priority Review US  Imfinzi for limited-stage small cell lung cancer whose disease has not progressed 
following platinum -based concurrent chemoradiotherap y. (ADRIATIC, August 
2024) 
Approval US  Imfinzi in combination with chemotherapy for the treatment of adult patients with 
resectable early-stage (IIA-IIIB) NSCLC and no known EGFR mutations or ALK 
rearrangements. (AEGEAN, August 2024) 
Phase III 
presentation: 
ESMO 
NIAGARA  In a planned interim analysis, patients treated with the Imfinzi perioperative regimen 
showed a 32% reduction in the risk of disease progression, recurrence, not 
undergoing surgery, or death versus the comparator arm (EFS HR 0.68; 95% CI 
0.56-0.82, p<0.0001). Estimated median EFS was not yet reached for the Imfinzi 
arm versus 46.1 months for the comparator arm. In addition, Imfinzi perioperative 
regimen reduced the risk of death by 25% versus neoadjuvant chemotherapy with 
radical cystectomy (OS HR 0.75; 95% CI 0.59-0.93, p=0.0106). (September 2024) 
Phase III 
presentation: 
ESMO 
HIMALAYA  At five years of follow-up, latest exploratory analysis of HIMALAYA showed that a 
single priming dose of Imjudo added to Imfinzi, called the STRIDE regimen (Single 
Tremelimumab Regular Interval Durvalumab), reduced the risk of death by 24% 
compared to sorafenib ( HR 0.76, 95% CI 0.65-0.89). An estimated 19.6% of 
patients treated with the STRIDE regimen were alive at five years versus 9.4% of 
those treated with sorafenib. (September 2024) 
 
Lynparza 
 
Event   Commentary 
Approval Europe  Imfinzi plus chemotherapy as 1st-line treatment followed by Lynparza and Imfinzi 
for patients with mismatch repair proficient disease. (DUO-E, August 2024) 
 
Enhertu 
 
Event   Commentary 
Approval China  Conditional approval as monotherapy for the treatment of adult patients with locally 
advanced or metastatic HER2 -positive gastric or gastroesophageal junction 
adenocarcinoma who have received two or more prior treatment regimens. 
(DESTINY-Gastric06, August 2024) 
Phase IIIb/IV 
presentation: 
ESMO 
DESTINY-
Breast12 
 Enhertu demonstrated substantial overall and intracranial clinical activity in a large 
cohort of patients with HER2 -positive metastatic breast cancer who have brain 
metastases and received no more than two prior lines of therapy in the metastatic 
setting with a 12-month PFS rate of 61.6%. (September 2024) 
Priority Review US  For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 
1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer 
who have received at least one endocrine therapy in the metastatic setting. 
(DESTINY-Breast06, October 2024) 
Approval China  Conditional approval as monotherapy for the treatment of adult patients with 
unresectable, locally advanced or metastatic NSCLC whose tumours have

===== SIDA 23 =====

23 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
activating HER2 mutations and who have received a prior systemic therapy. 
(DESTINY-Lung02, DESTINY-Lung05, October 2024) 
 
Calquence 
 
Event   Commentary 
Phase III trial 
readout 
AMPLIFY 
 
 Interim analysis of AMPLIFY Phase III trial showed a fixed duration of Calquence 
in combination with venetoclax, with or without obinutuzumab, demonstrated a 
statistically significant and clinically meaningful improvement in PFS compared to 
standard-of-care chemoimmunotherapy in previously untreated adult patients with 
chronic lymphocytic leukaemia. (July 2024) 
Priority Review US  For the treatment of adult patients with previously untreated mantle cell lymphoma. 
(ECHO, October 2024) 
 
Datopotamab deruxtecan (Dato-DXd) 
 
Event   Commentary 
Phase III 
presentation: 
WCLC 
TROPION-
Lung01 
 
 Exploratory analysis of the TROPION -Lung01 Phase III trial showed TROP2 as 
measured by AstraZeneca 's proprietary computational pathology platform, 
quantitative continuous scoring, was predictive of clinical outcomes in patients with 
advanced or metastatic NSCLC  who were treated with Dato -DXd. (September 
2024) 
Phase III 
presentation: 
WCLC 
TROPION-
Lung01 
 
 Demonstrated a clinically meaningful, but not statistically significant, trend toward 
improving OS with Dato -DXd compared to docetaxel in patients with locally 
advanced or metastatic non-squamous NSCLC treated with at least one prior line 
of therapy (14.6 versus 12.3 months; HR 0.84; 95% CI 0.68 -1.05). In the overall 
trial population, OS results numerically favoured Dato-DXd compared to docetaxel 
(12.9 versus 11.8 months) but did not reach statistical significance (HR 0.94, 95% 
CI 0.78-1.14, p=0.530). (September 2024) 
Phase III trial 
readout 
TROPION-
Breast01 
 TROPION-Breast01 Phase III trial of Dato-DXd compared to investigator's choice 
of chemotherapy, which previously met the dual primary endpoint of PFS, did not 
achieve statistical significance in the final OS analysis in patients with inoperable or 
metastatic hormone receptor-positive, HER2-low or negative (IHC 0, IHC 1+ or IHC 
2+/ISH-) breast cancer previously treated with endocrine -based therapy and at 
least one systemic therapy. (September 2024) 
Regulatory 
update 
US  Submission of a new Biologics License Application for accelerated approval for 
Dato-DXd for the treatment of adult patients with locally advanced or metastatic 
EGFRm NSCLC who have received prior systemic therapies, including an EGFR-
directed therapy. Voluntarily withdrawal of the Biologics License Application for 
Dato-DXd for patients with advanced or metastatic non-squamous NSCLC based 
on the TROPION-Lung01 Phase III trial. An additional trial in biomarker -positive 
patients in the 2nd line non-squamous NSCLC setting is also planned. (TROPION-
Lung05, TROPION-PanTumor01, TROPION-Lung01, November 2024) 
 
Zoladex 
 
Event   Commentary 
Approval China 
 
 Zoladex 10.8mg for breast cancer in pre- and perimenopausal women suitable for 
hormonal manipulation. (Study 11, October 2024) 
 
BioPharmaceuticals - CVRM 
 
Wainua 
 
Event   Commentary 
CHMP positive 
opinion 
EU 
 
 For the treatment of hereditary transthyretin-mediated amyloidosis in adult patients 
with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR -PN or 
ATTRv-PN. (NEURO-TTRansform, October 2024)

===== SIDA 24 =====

24 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
BioPharmaceuticals - R&I 
 
Airsupra 
 
Event   Commentary 
Phase III trial 
readout 
BATURA 
 
 Interim analysis of the Phase IIIb BATURA trial showed Airsupra met the primary 
endpoint, demonstrating a statistically significant and clinically meaningful reduction 
in the risk of a severe exacerbation when used as an as-needed rescue medication 
in response to symptoms compared to as-needed albuterol. (October 2024) 
 
Breztri 
 
Event   Commentary 
Clinical program 
completion 
NGP 
 
 Completion of the clinical programme to support the transition of Breztri to next-
generation propellant with near-zero Global Warming Potential. (September 2024) 
A Marketing Authorisation Application for Breztri with the next-generation propellant 
has been accepted by the European Medicines Agency (November 2024 ). 
Additional submissions in the UK and China expected before the end of 2024. 
(November 2024) 
 
Fasenra 
 
Event   Commentary 
Approval US  For the treatment  of adult patients with eosinophilic granulomatosis with 
polyangiitis. (MANDARA, September 2024) 
CHMP positive 
opinion 
EU  As an add-on treatment for adult patients with relapsing or refractory eosinophilic 
granulomatosis with polyangiitis. (MANDARA, September 2024) 
Approval China  For maintenance treatment of patients 12 years of age and older with severe 
eosinophilic asthma. (MIRACLE, August 2024) 
Phase III trial 
update 
ORCHID 
 
 The Phase III ORCHID trial assessing Fasenra in chronic rhinosinusitis with nasal 
polyps and asthma did not meet the primary endpoints of improvement in the size 
of nasal polyps and in nasal blockage. The safety and tolerability profile for Fasenra 
in the trial was consistent with the known profile of the treatment. Results from 
ORCHID will be shared with the scientific community in the future.  (November 
2024) 
 
Tezspire 
 
Event   Commentary 
Phase III trial 
readout 
WAYPOINT 
 
 Tezspire met both co -primary endpoints, demonstrating a statistically significant 
and clinically meaningful reduction in nasal polyp size and improved nasal 
congestion compared to placebo. (November 2024) 
 
BioPharmaceuticals - V&I 
 
FluMist 
 
Event   Commentary 
Approval US  For self-administration by adults up to 49  years of age or as administered by a 
parent/caregiver to individuals 2 -17 years of age.  FluMist is the only influenza 
vaccine approved for self-administration in the US. (September 2024) 
 
Rare Disease  
 
Alexion, AstraZeneca Rare Disease, presented data from its leading gMG portfolio at the American Association 
of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and the Myasthenia Gravis Foundation of 
America Scientific Session in October 2024.

===== SIDA 25 =====

25 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
The company presented 11 abstracts, spanning clinical and real-world data, which add to the extensive body of 
evidence supporting the safety and efficacy of  Ultomiris and Soliris in treating anti -acetylcholine receptor 
antibody-positive gMG, and offer new insights to inform clinical practice. 
 
Koselugo 
 
Event   Commentary 
Phase III trial 
readout 
KOMET  Positive high-level results of the Phase III KOMET trial in adults with  NF1-PN 
showed that Koselugo met its primary endpoint demonstrating a statistically 
significant and clinically meaningful ORR versus placebo in these adult 
patients. (November 2024) 
 
Interim financial statements 
 
Table 18: Condensed consolidated statement of comprehensive income: 9M 2024 
 
For the nine months ended 30 September  2024  2023  
  $m  $m  
Total Revenue  39,182  33,787  
Product Sales  37,576  32,466  
Alliance Revenue  1,498  1,004  
Collaboration Revenue  108  317  
Cost of sales  (7,482) (5,960) 
Gross profit  31,700  27,827  
Distribution expense  (412) (394) 
Research and development expense  (8,906) (7,862) 
Selling, general and administrative expense  (14,567) (13,845) 
Other operating income and expense  152  1,233  
Operating profit  7,967  6,959  
Finance income  394  236  
Finance expense  (1,313) (1,181) 
Share of after tax losses in associates and joint ventures  (23) (12) 
Profit before tax  7,025  6,002  
Taxation  (1,484) (1,000) 
Profit for the period  5,541  5,002  
Other comprehensive income:    
Items that will not be reclassified to profit or loss:     
Remeasurement of the defined benefit pension liability  136  (1) 
Net gains on equity investments measured at fair value through other 
comprehensive income 
 264  45  
Fair value movements related to own credit risk on bonds designated as fair value 
through profit or loss 
 12  5  
Tax on items that will not be reclassified to profit or loss  (50) -  
  362  49  
Items that may be reclassified subsequently to profit or loss:     
Foreign exchange arising on consolidation  543  (201) 
Foreign exchange arising on designated liabilities in net investment hedges  (84) (63) 
Fair value movements on cash flow hedges  (42) 62  
Fair value movements on cash flow hedges transferred to profit and loss  1  28  
Fair value movements on derivatives designated in net investment hedges  13  47  
Gains/(costs) of hedging  2  (3) 
Tax on items that may be reclassified subsequently to profit or loss  16  (7) 
  449  (137) 
Other comprehensive income/(expense), net of tax  811  (88) 
Total comprehensive income for the period  6,352  4,914  
Profit attributable to:    
Owners of the Parent  5,535  4,995  
Non-controlling interests  6  7

===== SIDA 26 =====

26 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
  5,541  5,002  
Total comprehensive income attributable to:      
Owners of the Parent  6,346  4,907  
Non-controlling interests  6  7  
  6,352  4,914  
Basic earnings per $0.25 Ordinary Share  $3.57  $3.22  
Diluted earnings per $0.25 Ordinary Share  $3.54  $3.20  
Weighted average number of Ordinary Shares in issue (millions)  1,550  1,549  
Diluted weighted average number of Ordinary Shares in issue (millions)  1,562  1,560  
 
Table 19: Condensed consolidated statement of comprehensive income: Q3 2024 
 
For the quarter ended 30 September    
  2024  2023  
  $m  $m  
Total Revenue  13,565  11,492  
Product Sales  12,947  11,018  
Alliance Revenue  559  377  
Collaboration Revenue  59  97  
Cost of sales  (3,081) (2,095) 
Gross profit  10,484  9,397  
Distribution expense  (145) (129) 
Research and development expense  (3,115) (2,584) 
Selling, general and administrative expense  (5,143) (4,800) 
Other operating income and expense  25  70  
Operating profit  2,106  1,954  
Finance income  183  101  
Finance expense  (457) (392) 
Share of after tax losses in associates and joint ventures  (4) (11) 
Profit before tax  1,828  1,652  
Taxation  (395) (274) 
Profit for the period  1,433  1,378  
Other comprehensive income:    
Items that will not be reclassified to profit or loss:     
Remeasurement of the defined benefit pension liability  35  (8) 
Net gains on equity investments measured at fair value through other 
comprehensive income 
 175  93  
Fair value movements related to own credit risk on bonds designated as fair value 
through profit or loss 
 -  1  
Tax on items that will not be reclassified to profit or loss  (23) 5  
  187  91  
Items that may be reclassified subsequently to profit or loss:     
Foreign exchange arising on consolidation  1,097  (306) 
Foreign exchange arising on designated liabilities in net investment hedges  12  38  
Fair value movements on cash flow hedges  96  (27) 
Fair value movements on cash flow hedges transferred to profit and loss  (101) 99  
Fair value movements on derivatives designated in net investment hedges  (32) 7  
Costs of hedging  (12) (2) 
Tax on items that may be reclassified subsequently to profit or loss  (22) (19) 
  1,038  (210) 
Other comprehensive income/(expense), net of tax  1,225  (119) 
Total comprehensive income for the period  2,658  1,259  
Profit attributable to:    
Owners of the Parent  1,429  1,374  
Non-controlling interests  4  4  
  1,433  1,378

===== SIDA 27 =====

27 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Total comprehensive income attributable to:      
Owners of the Parent  2,654  1,255  
Non-controlling interests  4  4  
  2,658  1,259  
Basic earnings per $0.25 Ordinary Share  $0.92   $0.89  
Diluted earnings per $0.25 Ordinary Share  $0.91   $0.88  
Weighted average number of Ordinary Shares in issue (millions)  1,550   1,549  
Diluted weighted average number of Ordinary Shares in issue (millions)  1,562   1,560  
 
Table 20: Condensed consolidated statement of financial position 
 
  At 30 Sep 
2024  
At 31 Dec 
2023  
At 30 Sep 
2023  
  $m  $m  $m  
Assets  
Non-current assets 
    
Property, plant and equipment  10,135  9,402  8,723 
Right-of-use assets  1,378  1,100  977 
Goodwill  21,139  20,048  19,939 
Intangible assets  39,394  38,089  37,687 
Investments in associates and joint ventures  290  147  62 
Other investments  1,855  1,530  1,228 
Derivative financial instruments  319  228  151 
Other receivables  915  803  761 
Deferred tax assets  5,342  4,718  4,057 
  80,767  76,065  73,585 
Current assets     
Inventories  5,662  5,424  5,292 
Trade and other receivables  11,879  12,126  11,300 
Other investments  133  122  244 
Derivative financial instruments  16  116  97 
Income tax receivable  1,668  1,426  697 
Cash and cash equivalents  4,797  5,840  4,871 
  24,155  25,054  22,501 
Total assets  104,922  101,119  96,086 
Liabilities 
Current liabilities 
    
Interest-bearing loans and borrowings  (1,253) (5,129) (5,372) 
Lease liabilities  (317) (271) (235) 
Trade and other payables  (21,684) (22,374) (20,542) 
Derivative financial instruments  (17) (156) (83) 
Provisions  (1,187) (1,028) (1,193) 
Income tax payable  (1,468) (1,584) (1,163) 
  (25,926) (30,542) (28,588) 
Non-current liabilities     
Interest-bearing loans and borrowings  (28,887) (22,365) (22,225) 
Lease liabilities  (1,105) (857) (744) 
Derivative financial instruments  (34) (38) (75) 
Deferred tax liabilities  (3,568) (2,844) (2,752) 
Retirement benefit obligations  (1,361) (1,520) (1,048) 
Provisions  (1,063) (1,127) (1,189) 
Income tax payable  (174) -  - 
Other payables  (1,999) (2,660) (2,244) 
  (38,191) (31,411) (30,277) 
Total liabilities  (64,117) (61,953) (58,865) 
Net assets  40,805  39,166  37,221  
Equity  
Capital and reserves attributable to equity holders of the Parent

===== SIDA 28 =====

28 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
  At 30 Sep 
2024  
At 31 Dec 
2023  
At 30 Sep 
2023  
  $m  $m  $m  
Share capital  388  388  387 
Share premium account  35,203  35,188  35,166 
Other reserves  1,990  2,065  2,078 
Retained earnings  3,138  1,502  (434) 
  40,719  39,143  37,197  
Non-controlling interests  86  23  24  
Total equity  40,805  39,166  37,221  
 
Table 21: Condensed consolidated statement of changes in equity 
  
 
Share 
capital 
Share 
premium 
account 
Other 
reserves 
Retained 
earnings 
Total 
attributable 
to owners of 
the parent 
Non-
controlling 
interests 
Total 
equity 
   $m  $m  $m  $m  $m  $m  $m  
At 1 Jan 2023  387  35,155  2,069  (574) 37,037  21  37,058  
Profit for the period  -  -  -  4,995  4,995  7  5,002  
Other comprehensive expense    -  -  -  (88) (88) -  (88) 
Transfer to other reserves  -  -  9  (9) -  -  -  
Transactions with owners                
Dividends  -  -  -  (4,487) (4,487) -  (4,487) 
Dividends paid to non-controlling 
interests 
 -  -  -  -  -  (4) (4) 
Issue of Ordinary Shares  -  11  -  -  11  -  11  
Share-based payments charge 
for the period 
 -  -  -  429  429  -  429  
Settlement of share plan awards  -  -  -  (700) (700) -  (700) 
Net movement  -  11  9  140  160  3  163  
At 30 Sep 2023  387  35,166  2,078  (434) 37,197  24  37,221  
         
At 1 Jan 2024  388  35,188  2,065  1,502  39,143  23  39,166  
Profit for the period  -  -  -  5,535  5,535  6  5,541  
Other comprehensive income    -  -  -  811  811  -  811  
Transfer to other reserves  -  -  1  (1) -  -  -  
Transactions with owners         
Dividends  -  -  -  (4,602) (4,602) -  (4,602) 
Dividends paid to non-controlling 
interests 
 -  -  -  -  -  (4) (4) 
Issue of Ordinary Shares  -  15  -  -  15  -  15  
Changes in non-controlling 
interests 
 -  -  -  -  -  61  61  
Movement in shares held by 
Employee Benefit Trust 
 -  -  (76) -  (76) -  (76) 
Share-based payments charge 
for the period 
 -  -  -  487  487  -  487  
Settlement of share plan awards  -  -  -  (594) (594) -  (594) 
Net movement  -  15  (75) 1,636  1,576  63  1,639  
At 30 Sep 2024  388  35,203  1,990  3,138  40,719  86  40,805  
 
Table 22: Condensed consolidated statement of cash flows: 9M 2024 
 
For the nine months ended 30 September  2024  2023  
 $m  $m  
 
Cash flows from operating activities    
Profit before tax  7,025  6,002  
Finance income and expense  919  945  
Share of after tax losses of associates and joint ventures  23  12

===== SIDA 29 =====

29 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Depreciation, amortisation and impairment  4,351  4,060  
Movement in working capital and short-term provisions  (543) 150  
Gains on disposal of intangible assets  (34) (247) 
Fair value movements on contingent consideration arising from business 
combinations 
 251  202  
Non-cash and other movements  15  (623) 
Cash generated from operations  12,007  10,501  
Interest paid  (1,075) (826) 
Tax paid  (1,978) (1,710) 
Net cash inflow from operating activities  8,954  7,965  
 
Cash flows from investing activities    
Acquisition of subsidiaries, net of cash acquired  (2,771) (189) 
Payments upon vesting of employee share awards attributable to business 
combinations 
 -  (84) 
Payment of contingent consideration from business combinations  (737) (610) 
Purchase of property, plant and equipment  (1,216) (836) 
Disposal of property, plant and equipment  53  131  
Purchase of intangible assets  (2,415) (1,996) 
Disposal of intangible assets  107  288  
Movement in profit-participation liability  -  190  
Purchase of non-current asset investments  (96) (109) 
Disposal of non-current asset investments  73  32  
Movement in short-term investments, fixed deposits and other investing 
instruments 
 67  (12) 
Payments to associates and joint ventures  (158) -  
Disposal of investments in associates and joint ventures  13  -  
Interest received  281  208  
Net cash (outflow) from investing activities  (6,799) (2,987) 
Net cash inflow before financing activities  2,155  4,978  
 
Cash flows from financing activities    
Proceeds from issue of share capital  15  12  
Own shares purchased by Employee Benefit Trust  (81) -  
Issue of loans and borrowings   6,492  3,816  
Repayment of loans and borrowings  (4,647) (4,655) 
Dividends paid  (4,626) (4,479) 
Hedge contracts relating to dividend payments  16  (19) 
Repayment of obligations under leases  (233) (194) 
Movement in short-term borrowings  572  110  
Payment of Acerta Pharma share purchase liability  (833) (867) 
Net cash (outflow) from financing activities  (3,325) (6,276) 
Net (decrease) in Cash and cash equivalents in the period  (1,170) (1,298) 
Cash and cash equivalents at the beginning of the period  5,637  5,983  
Exchange rate effects  (32) (66) 
Cash and cash equivalents at the end of the period  4,435  4,619  
Cash and cash equivalents consist of:      
Cash and cash equivalents  4,797  4,871  
Overdrafts  (362) (252) 
  4,435  4,619  
 
Notes to the Interim financial statements 
 
Note 1: Basis of preparation and accounting policies 
 
These unaudited condensed consolidated Interim financial statements for the nine months ended 30 September 
2024 have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting' 
(IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European 
Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United

===== SIDA 30 =====

30 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Kingdom's Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to 
companies reporting under those standards.  
 
The unaudited Interim financial statements for the nine months ended 30 September 2024  were approved by 
the Board of Directors for publication on 12 November 2024. 
 
This results announcement does not constitute statutory accounts of the Group within the meaning of sections 
434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 
31 December 2023 were prepared in accordance with UK-adopted international accounting standards and with 
the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS 
Accounting Standards  as issued by the IASB and International Accounting Standards as adopted by the 
European Union. Except for the estimation of the interim income tax charge, the Interim financial statements 
have been prepared applying the accounting policies that were applie d in the preparation of the Group 's 
published consolidated financial statements for the year ended 31 December 2023. 
 
The comparative figures for the financial year ended 31 December 2023 are not the Group's statutory accounts 
for that financial year. Those accounts have been reported on by the Group's auditors and have been delivered 
to the Registrar of Companies; their report was (i) unqualified, (ii) did not include a reference to any matters to  
which the auditors drew attention by way of emphasis without qualifying their report, and (iii) did not contain a  
statement under section 498(2) or (3) of the Companies Act 2006. 
 
Going concern 
The Group has considerable financial resources available. As at 30 September 2024, the Group has $11.7bn 
in financial resources (cash and cash equivalent balances of $4.8bn and undrawn committed bank facilities of 
$6.9bn, with $1.6bn of borrowings due within one year). These facilities contain no financial covenants and were 
undrawn at 30 September 2024. There are $4.9bn of undrawn committed bank facilities are available until April 
2029. Additionally, there are a further $2.0bn undrawn committed bank facilities available until February 2025. 
 
The Group's revenues are largely derived from sales of medicines covered by patents, which provide a relatively 
high level of resilience and predictability to cash inflows, although government price interventions in response 
to budgetary constraints are expected to continue to adversely affect revenues in some of our significant 
markets. The Group, however, anticipates new revenue streams from both recently launched medicines and 
those in development, and the Group has a wide diversity of customers and suppliers across different 
geographic areas. 
 
Consequently, the Directors believe that, overall, the Group is well  placed to manage its business risks 
successfully. Accordingly, they continue to adopt the going concern basis in preparing the  Interim financial 
statements. 
 
Legal proceedings 
The information contained in Note 6 updates the disclosures concerning legal proceedings and contingent 
liabilities in the Group's Annual Report and Form 20-F Information 2023. 
 
Employee Benefit Trust  
Following an amendment to the Employee Benefit Trust (EBT) Deed on 10  June 2024, AstraZeneca obtained 
control and commenced consolidation of the EBT. Accordingly, cash paid on purchases of AstraZeneca 
Ordinary shares or American Deposit ary Receipts  is presented within Financing activities in the Cash flow 
statement. 
 
Note 2: Intangible assets 
 
In accordance with IAS 36 'Impairment of Assets', reviews for triggers of impairment or impairment reversals at 
an individual asset or cash generating unit level were conducted, and impairment tests carried out where triggers 
were identified. Following a strategic review of our portfolio priorities, the business decision was made to cease 
promotional activity for Andexxa resulting in impairment charges of $504m recorded against the Andexxa 
intangible asset under value in use model applying a discount rate of 7.5% (revised carrying amount: $nil), total 
net impairment charges of $525m have been recorded against intangible assets during the nine months ended 
30 September 2024 (9M 2023: $376m net charge). In 9M 2023, net impairment charges included the $244m 
impairment of the ALXN1840 intangible asset, following the decision to discontinue th is development 
programme in Wilson's disease.

===== SIDA 31 =====

31 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 
The acquisition of Icosavax, Inc. completed on 19 February 2024 . The transaction is recorded as an asset 
acquisition based on the concentration test permitted under IFRS 3 'Business Combinations', with consideration 
of $841m principally relating to $639m of intangible assets, $141m of cash and cash equivalents and $51m of 
marketable securities. Contingent consideration of up to $300m could be paid on achievement of regulatory and 
sales milestones; these potential liabilities would be reco rded when the relevant recognition event for a 
regulatory or sales milestone is achieved.  
 
The acquisition of Amolyt Pharma completed on 15 July 2024. The transaction is recorded as an asset 
acquisition based on the concentration test permitted under IFRS 3 'Business Combinations', with consideration 
of $857m principally relating to $800m of intangible assets and $98m of cash and cash equivalents. Contingent 
consideration of up to $250m could be paid on achievement of a regulatory milestone; this potential liability 
would be recorded when the relevant recognition event for a regulatory milestone is achieved. 
 
Note 3: Net debt 
 
The table below provides an analysis of Net debt and a reconciliation of Net Cash flow to the movement in Net 
debt. The Group monitors Net debt as part of its capital  management policy as described in Note 28 of the 
Annual Report and Form 20-F Information 2023. Net debt is a non-GAAP financial measure. 
 
Table 23: Net debt 
 
  At 1 Jan 
2024 
Cash 
flow 
Acquisitions Non-cash  
& other 
Exchange 
movements 
At 30 Sep 
2024 
  $m $m $m $m $m $m 
Non-current instalments of loans  (22,365) (6,499) (3) 69  (89) (28,887) 
Non-current instalments of leases  (857) 1  (12) (233) (4) (1,105) 
Total long-term debt  (23,222) (6,498) (15) (164) (93) (29,992) 
Current instalments of loans  (4,614) 4,586  (9) (3) 28  (12) 
Current instalments of leases  (271) 271  (6) (311) -  (317) 
Commercial paper  -  (472) -  -  -  (472) 
Collateral received from derivative 
counterparties 
  
(215) (72) -  -  -  (287) 
Other short-term borrowings excluding 
overdrafts 
  
(97) (28) -  (1) 6  (120) 
Overdrafts  (203) (158) -  1  (2) (362) 
Total current debt  (5,400) 4,127  (15) (314) 32  (1,570) 
Gross borrowings  (28,622) (2,371) (30) (478) (61) (31,562) 
Net derivative financial instruments  150  41  -  93  -  284  
Net borrowings  (28,472) (2,330) (30) (385) (61) (31,278) 
Cash and cash equivalents  5,840  (1,254) 242  (1) (30) 4,797  
Other investments - current  122  (67) 87  -  (9) 133  
Cash and investments  5,962  (1,321) 329  (1) (39) 4,930  
Net debt  (22,510) (3,651) 299  (386) (100) (26,348) 
 
Net debt increased by $3,838m in the nine months to $26,348m. Details of the committed undrawn bank facilities 
are disclosed within the going concern section of Note 1.  Non-cash movements in the period include fair value 
adjustments under IFRS 9 'Financial Instruments'.  
 
In February 2024, AstraZeneca issued the following: 
 
- $1,250m of fixed-rate notes with a coupon of 4.8% maturing in February 2027 
- $1,250m of fixed-rate notes with a coupon of 4.85% maturing in February 2029 
- $1,000m of fixed-rate notes with a coupon of 4.9% maturing in February 2031 
- $1,500m of fixed-rate notes with a coupon of 5% maturing in February 2034 
 
In August 2024, AstraZeneca issued the following: 
 
- €650m of fixed-rate notes with a coupon of 3.121% maturing in August 2030 
- €750m of fixed-rate notes with a coupon of 3.278% maturing in August 2033 
 
AstraZeneca repaid two bonds of carrying value  $2,569m and floating rate bank loans of $2,000m during the 
nine months which are included in the cash outflow from Repayment of loans and borrowings of $4,647m.

===== SIDA 32 =====

32 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
The Group has agreements with some bank counterparties whereby the parties agree to post cash collateral 
on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions 
above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 September 
2024 was $287m (31 Dec ember 2023: $215m) and the carrying value of such cash collateral posted by the 
Group at 30 September 2024 was $68m (31 December 2023: $102m). 
 
The equivalent GAAP measure to Net debt is 'liabilities arising from financing activities ', which excludes the 
amounts for cash and overdrafts, other investments and non -financing derivatives shown above and includes 
the Acerta Pharma share purchase liability of $nil (31 December 2023: $833m). 
 
During the quarter ended 30 September 2024, Standard  and Poor's upgraded the Company 's solicited long 
term credit rating to A+ from A. The short term rating remained at A-1. There were no changes to Moody's credit 
ratings (long term: A2; short term: P-1). 
 
Note 4: Financial Instruments 
 
As detailed in the Group 's most recent annual financial statements, the principal financial instruments consist 
of derivative financial instruments, other investments, trade and other receivables, cash and cash equivalents, 
trade and other payables, lease liabilities and interest-bearing loans and borrowings. 
 
The Group has certain equity investments that are categorised as Level 3 in the fair value hierarchy that are 
held at $370m (31 December 2023: $313m)  and for which a fair value gain of $nil has been recognised in the 
nine months ended 30 September 2024 (9M 2023: $17m). In the absence of specific market data, these unlisted 
investments are held at fair value based on the cost of investment and adjust ed as necessary for impairments 
and revaluations on new funding rounds, which are seen to approximate the fair value. All other fair value gains 
and/or losses that are presented in Net gains  on equity investments measured at fair value through other 
comprehensive income, in the Condensed consolidated statement of comprehensive income for the nine 
months ended 30 September 2024, are Level 1 fair value measurements, valued based on quoted prices in 
active markets. 
  
Financial instruments measured at fair value include $1,920m of  other investments, $3,408m held in money -
market funds and $284m of derivatives as at 30 September 2024. With the exception of derivatives being Level 
2 fair valued, and certain equity instruments of $379m categorised as Level 3, the aforementioned balances are 
Level 1 fair valued. Financial instruments measured at amortised cost include $68m of cash collateral pledged 
to counterparties. The total fair value of interest -bearing loans and borrowings at 30 September 2024, which 
have a carrying value of $31,562m in the Condensed consolidated statement of financial position, was 
$31,396m. 
 
Table 24: Financial instruments - contingent consideration 
 
  2024  2023 
 
  Diabetes 
alliance Other Total Total 
  $m $m $m $m 
At 1 January  1,945  192  2,137  2,222  
Additions through business combinations  -  198  198  60  
Settlements  (736) (1) (737) (610) 
Revaluations  220  32  252  202  
Discount unwind  77  8  85  99  
At 30 September  1,506 429 1,935 1,973 
 
Contingent consideration arising from business combinations is fair valued using decision -tree analysis, with 
key inputs including the probability of success, consideration of potential delays and the expected levels of 
future revenues. 
 
The contingent consideration balance relating to BMS 's share of the global diabetes alliance of $1,506m 
(31 December 2023: $1,945m) would increase/decrease by $151m with an increase/decrease in sales of 10%, 
as compared with the current estimates. 
 
Note 5: Business combinations 
 
Gracell

===== SIDA 33 =====

33 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 
On 22 February 2024, AstraZeneca completed the acquisition of Gracell Biotechnologies Inc. (Gracell), a global 
clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and 
autoimmune diseases.  
 
The purchase price allocation review has been completed, currently there are no changes to the amounts 
reported in the H1 and Q2 2024 results announcement. The transaction is recorded as a business combination 
using the acquisition method of accounting in accordance with IFRS 3 'Business Combinations'.  
 
The total consideration fair value of $1,037m includes cash consideration of $983m and future regulatory 
milestone-based consideration of $54m. Intangible assets recognised relate to products in development, 
principally AZD0120. Goodwill of $136m has been recognised .  Gracell's results have been consolidated into 
the Group's results from 22 February 2024. 
 
Fusion 
 
On 4 June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc., (Fusion) a clinical -
stage biopharmaceutical company developing next-generation radioconjugates.  
 
The purchase price allocation review has been  completed, currently there are no changes to the amounts 
reported in the H1 and Q2 2024 results announcement. The transaction is recorded as a business combination 
using the acquisition method of accounting in accordance with IFRS 3 'Business Combinations'.  
 
The total consideration fair value of $2,195m includes cash consideration of $2,051m and future regulatory 
milestone-based consideration of $144m. Intangible assets relating to products in development comprise the 
FPI-2265 ($848m), FPI -2059 ($165m) and AZD 2068 ($313m) programmes. Goodwill of $947m has been 
recognised. Fusion's results have been consolidated into the Group's results from 4 June 2024. 
 
Note 6: Legal proceedings and contingent liabilities 
 
AstraZeneca is involved in various legal proceedings considered typical to its business, including litigation and 
investigations, including Government investigations, relating to product liability, commercial disputes, 
infringement of intellectual property  (IP) rights, the validity of certain patents, anti -trust law and sales and 
marketing practices. The matters discussed below constitute the more significant developments since 
publication of the disclosures concerning legal proceedings in the Company's Ann ual Report and Form 20 -F 
Information 2023 and the Interim Financial Statements for the six months ended 30 June 2024 (the Disclosures). 
Information about the nature and facts of the cases is disclosed in accordance with IAS 37.  
 
As discussed in the Disclosures, the majority of claims involve highly complex issues. Often these issues are 
subject to substantial uncertainties and, therefore, the probability of a loss, if any, being sustained and/or an 
estimate of the amount of any loss is difficult to ascertain. 
 
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been assessed 
and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate 
of the loss, AstraZeneca records the  loss absorbed or makes a provision for its best estimate of the expected 
loss. The position could change over time and the estimates that the Company made, and upon which the 
Company have relied in calculating these provisions are inherently imprecise. Th ere can, therefore, be no 
assurance that any losses that result from the outcome of any legal proceedings will not exceed the amount of 
the provisions that have been booked in the accounts. The major factors causing this uncertainty are described 
more fully in the Disclosures and herein. 
 
AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP.  
 
Matters disclosed in respect of the third quarter of 2024 and to 12 November 2024  
 
Table 25: Patent litigation 
 
Legal proceedings brought against AstraZeneca 
Faslodex patent 
proceedings, Japan 
 
  In 2021 in Japan, AstraZeneca received notice from the Japan Patent Office (JPO) that 
Sandoz K.K. (Sandoz) and Sun Pharma Japan Ltd. (Sun) were seeking to invalidate the 
Faslodex formulation patent.

===== SIDA 34 =====

34 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Considered to be a 
contingent asset 
 AstraZeneca defended the challenged patent and Sun withdrew from the JPO patent 
challenge.   
 In July 2023, the JPO issued a final decision upholding various claims of the challenged 
patent and determining that other patent claims were invalid.   
 In August 2023, Sandoz appealed the JPO decision to the Japan IP High Court (High 
Court). 
 In October 2024, the High Court affirmed the decision by the JPO.  
Tagrisso patent 
proceedings, US 
 
Considered to be a 
contingent liability 
  In September 2021, Puma Biotechnology, Inc. (Puma) and Wyeth LLC (Wyeth) filed a 
patent infringement lawsuit in the US District Court for the District of Delaware (District 
Court) against AstraZeneca relating to Tagrisso.  
 In March 2024, the District Court dismissed Puma.  
 The jury trial, with Wyeth as the plaintiff, took place in May 2024. The jury found Wyeth's 
patents infringed and awarded Wyeth $107.5m in past damages. The jury also found that 
the infringement was not wilful.  
 In proceedings following the jury award, the District Court rejected AstraZeneca's 
indefiniteness and equitable defences but granted judgment as a matter of law in favour 
of AstraZeneca on the grounds that the patents were invalid for lack of written description 
and enablement. Wyeth has filed an appeal.  
Legal proceedings brought by AstraZeneca 
Lokelma patent 
proceedings, US 
 
Considered to be a 
contingent asset 
  In August 2022, in response to Paragraph IV notices, AstraZeneca initiated ANDA 
litigation against multiple generic filers in the US District Court for the District of Delaware 
(District Court). AstraZeneca alleged that a generic version of Lokelma would infringe 
patents that are owned or licensed by AstraZeneca. 
 AstraZeneca has entered into separate settlement agreements with four generic 
manufacturers which resulted in dismissal of the corresponding litigations.  
 Additional proceedings with the remaining generic manufacturer are ongoing in the 
District Court. Trial is scheduled for March 2025. 
Soliris patent 
proceedings, Canada  
 
Considered to be a 
contingent asset 
  In May 2023, Alexion initiated patent litigation in Canada alleging that Amgen 
Pharmaceuticals, Inc.'s (Amgen) biosimilar eculizumab product will infringe Alexion 
patents.  
 In September 2023, Alexion initiated patent litigations in Canada alleging that Samsung 
Bioepis Co. Ltd.'s (Samsung) biosimilar eculizumab product will infringe Alexion 
patents. The filing of the litigation triggered an automatic 24-month stay of the approval of 
each defendant's biosimilar eculizumab product.  
 Trial against Amgen is scheduled to begin in January 2025 while trial against Samsung is 
scheduled to begin in June 2025. 
 In July and August 2023, in Canada, both Amgen and Samsung brought actions 
challenging the validity of Alexion's patent relating to the use of eculizumab in treating 
aHUS. Trial is scheduled to begin in November 2025. 
Soliris patent 
proceedings, US  
 
Matter concluded 
  In January 2024, Alexion initiated patent infringement litigation against Samsung Bioepis 
Co. Ltd. (Samsung) in the US District Court for the District of Delaware (District Court) 
alleging that Samsung's biosimilar eculizumab product, for which Samsung is currently 
seeking FDA approval, will infringe six Soliris-related patents.  
 Five of the six asserted patents were also the subject of inter partes review proceedings 
before the US Patent and Trademark Office. 
 Alexion filed a motion for a preliminary injunction seeking to enjoin Samsung from 
launching its biosimilar eculizumab product upon FDA approval. The District Court denied 
Alexion's motion and Alexion appealed that decision.  
 In August 2024, the parties reached resolution of the matter. All legal proceedings in the 
US courts have terminated, as have the inter partes review proceedings.  
Tagrisso patent 
proceedings, Russia 
 
Considered to be a 
contingent asset 
  In Russia, in August 2023, AstraZeneca filed lawsuits in the Arbitration Court of the 
Moscow Region (Court) against the Ministry of Health of the Russian Federation and 
Axelpharm LLC (Axelpharm) related to Axelpharm's improper use of AstraZeneca's 
information to obtain authorisation to market a generic version of Tagrisso. In December 
2023, the Court dismissed the lawsuit against the Ministry of Health of the Russian 
Federation. The appellate court affirmed the dismissal in March 2024. AstraZeneca filed a 
further appeal, which was dismissed in July 2024. The lawsuit against Axelpharm was 
dismissed in September 2024, and AstraZeneca appealed.

===== SIDA 35 =====

35 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 In November 2023, Axelpharm filed a compulsory licensing action against AstraZeneca in 
the Court related to a patent that covers Tagrisso. The compulsory licensing action 
remains pending. AstraZeneca has also challenged before the Russian Patent and 
Trademark Office (PTO) the validity of the Axelpharm patent on which the compulsory 
licensing action is predicated; in August 2024, the PTO determined that Axelpharm's 
patent is invalid.  
 In July 2024, AstraZeneca filed a patent infringement lawsuit, which remains pending, 
and an unfair competition claim with the Federal Anti-Monopoly Service of Russia (FAS) 
against AxelPharm and others related to the securing of state contracts in Russia for its 
generic version of Osimertinib.  
 In August 2024, FAS initiated an unfair competition case against Axelpharm and 
OncoTarget based on AstraZeneca's unfair competition claim.  
 In November 2024, FAS determined that Axelpharm had committed unfair competition 
and that OncoTarget had not; FAS ordered Axelpharm to cease sales of its generic 
osimertinib and pay the Russian government the income it received from its sales of its 
generic osimertinib.  
 
Table 26: Commercial litigation 
 
Legal proceedings brought against AstraZeneca 
Amyndas Trade 
Secrets Litigation, US 
 
Considered to be a 
contingent liability 
  AstraZeneca has been defending a matter filed by Amyndas Pharmaceuticals Member 
P.C. and Amyndas Pharmaceuticals, LLC, in the US District Court for the District of 
Massachusetts alleging trade secret misappropriation and breach of contract claims 
against Alexion and Zealand Pharma U.S. Inc. related to Amyndas' C3 inhibitor 
candidate.   
 No trial date has been set. 
Caelum Trade Secrets 
Litigation, US  
 
Matter concluded 
  AstraZeneca has been defending a matter filed by the University of Tennessee 
Research Foundation in the US District Court for the Eastern District of Tennessee 
related to CAEL-101.   
 In September 2024, the parties resolved the matter by settlement.  
Seroquel XR Antitrust 
Litigation, US  
 
Considered to be a 
contingent liability 
  In 2019, AstraZeneca was named in several related complaints now proceeding in US 
District Court in Delaware (District Court), including several putative class action lawsuits 
that were purportedly brought on behalf of classes of direct purchasers or end payors of 
Seroquel XR, that allege AstraZeneca and generic drug manufacturers violated US 
antitrust laws when settling patent litigation related to Seroquel XR.  
 In July 2022, the District Court dismissed claims relating to one of the generic 
manufacturers while allowing claims relating to the second generic manufacturer to 
proceed. 
 In September 2024, AstraZeneca reached a settlement agreement with one of the plaintiff 
classes and the parties are now seeking judicial review and approval of the settlement.  
 Trial with the remaining class of plaintiffs is currently scheduled for May 2025.  
Syntimmune Milestone 
Litigation, US  
 
Considered to be a 
contingent liability 
  In connection with Alexion's acquisition of Syntimmune, Inc. (Syntimmune) in December 
2020, Alexion was served with a lawsuit filed by the stockholders' representative for 
Syntimmune in Delaware state court that alleged, among other things, breaches of the 
2018 merger agreement.  
 The stockholders' representative alleges that Alexion failed to meet its obligations under 
the merger agreement to use commercially reasonable efforts to achieve the milestones. 
Alexion also filed a claim for breach of the representations in the 2018 merger agreement.   
 A trial was held in July 2023. 
 The court issued a partial decision in September 2024, concluding that the first milestone 
was achieved, and that Alexion had breached its contractual obligation to use 
commercially reasonable efforts to achieve the milestones. The court has requested 
additional briefing regarding damages and further proceedings regarding Alexion's claim 
for breach.   
Viela Bio, Inc. 
Shareholder Litigation, 
US  
 
  In February 2023, AstraZeneca was served with a lawsuit filed in the Delaware state court 
against AstraZeneca and certain officers (collectively, Defendants), on behalf of a putative 
class of Viela Bio, Inc. (Viela) shareholders. The complaint alleged that the Defendants

===== SIDA 36 =====

36 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Considered to be a 
contingent liability 
breached their fiduciary duty to Viela shareholders in the course of Viela's 2021 merger 
with Horizon Therapeutics, plc.  
 In July 2024, the Court granted with prejudice AstraZeneca's motion to dismiss. 
 In August 2024, plaintiffs appealed the dismissal. 
 
Table 27: Government investigations and proceedings 
 
Legal proceedings brought by AstraZeneca 
340B State Litigation, 
US  
 
Considered to be a 
contingent asset 
  AstraZeneca has filed lawsuits against Arkansas, Kansas, Louisiana, Maryland, 
Minnesota, Mississippi, Missouri, and West Virginia challenging the constitutionality of 
each state's 340B statute.  
 In the Arkansas matter, trial is scheduled for April 2025. An intervenor has moved to 
dismiss AstraZeneca's complaint. 
 In the Louisiana matter, the Court granted the state's motion for summary judgment.  
AstraZeneca has filed an appeal.  
 In the Maryland matter, the Court has rejected AstraZeneca's preliminary injunction 
motion. The state's motion to dismiss remains pending. 
 In the Minnesota matter, the state has moved to dismiss AstraZeneca's complaint. 
 In the Mississippi matter, AstraZeneca has moved for a preliminary injunction. 
 The remaining matters are in their preliminary stages. 
 
Other 
 
Additional government inquiries 
As is true for most, if not all, major prescription pharmaceutical companies, AstraZeneca is currently involved in 
multiple inquiries into drug marketing and pricing practices. In addition to the investigations described above, 
various law enforcement offices have, from time to t ime, requested information from the Group. There have 
been no material developments in those matters. 
 
Note 7 
Table 28: 9M 2024 - Product Sales year-on-year analysis14 
 
 World US Emerging Markets Europe 
 
 
$m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg 
Oncology 14,934  18  21  6,870  22  3,445  18  28  3,000  24  23  
Tagrisso 4,877  11  15  1,996  19  1,365  8  16  956  16  16  
Imfinzi 3,463  18  22  1,883  18  365  37  61  695  30  29  
Calquence 2,321  26  27  1,617  21  116  68  90  489  38  38  
Lynparza 2,228  8  10  954  6  475  16  25  612  13  12  
Enhertu 397  n/m n/m -  -  258  n/m n/m 92  n/m n/m 
Zoladex 817  17  24  11  (4) 622  19  28  111  14  13  
Imjudo 208  30  32  134  25  11  n/m n/m 26  n/m n/m 
Truqap 267  n/m n/m 260  n/m 2  n/m n/m 2  n/m n/m 
Orpathys 34  4  7  -  -  34  4  7  -  -  -  
Others 322  (18) (12) 15  5  197  (18) (13) 17  (34) (34) 
BioPharmaceuticals: CVRM 9,316  18  21  2,221  13  4,146  18  24  2,385  31  30  
Farxiga 5,723  31  34  1,278  28  2,225  35  41  1,903  40  39  
Brilinta 992  -  1  543  (1) 232  4  11  203  -  (1) 
Crestor 892  4  9  33  (18) 726  7  12  32  (22) (22) 
Seloken/Toprol-XL 465  (6) (1) -  84  452  (6) (1) 10  27  27  
Lokelma 392  31  34  181  16  68  84  90  66  61  61  
roxadustat 257  23  26  -  -  257  23  26  -  -  -  
Andexxa 159  24  26  61  7  3  n/m n/m 60  38  37  
Wainua 44  n/m n/m 44  n/m -  -  -  -  -  -  
Others 392  (27) (26) 81  (52) 183  (19) (14) 111  (16) (15) 
BioPharmaceuticals: R&I 5,431  20  23  2,419  27  1,489  13  20  1,026  21  20  
Symbicort 2,195  19  22  887  51  653  9  19  415  2  1  
Fasenra 1,218  7  8  750  4  68  43  52  294  12  11  
Pulmicort 517  5  9  13  (39) 427  9  14  51  4  2  
Breztri 721  51  53  367  40  199  62  68  102  86  85  
Tezspire 168  n/m n/m -  -  8  n/m n/m 105  n/m n/m 
Saphnelo 327  71  72  294  65  5  n/m n/m 17  n/m n/m 
Airsupra 41  n/m n/m 41  n/m -  -  -  -  -  -  
Others 244  (26) (25) 67  (48) 129  (15) (12) 42  4  3  
BioPharmaceuticals: V&I 680  2  5  201  n/m 168  (7) 1  189  (6) (8) 
 
14 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to 
rounding, the sum of a number of dollar values and percentages may not agree to totals.

===== SIDA 37 =====

37 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Synagis 346  (10) (4) (1) n/m 168  6  15  80  (26) (27) 
Beyfortus 188  n/m n/m 148  n/m -  n/m n/m 39  n/m n/m 
FluMist 109  40  37  26  61  -  n/m n/m 61  5  1  
COVID-19 mAbs 31  (75) (75) 28  n/m -  n/m n/m 3  (59) (60) 
Others 6  (79) (80) -  -  -  (99) n/m 6  (43) (45) 
Rare Disease 6,391  10  14  3,842  11  628  29  56  1,189  2  1  
Ultomiris 2,835  32  35  1,629  29  92  97  n/m 649  31  30  
Soliris 2,045  (16) (11) 1,170  (11) 365  8  39  346  (35) (35) 
Strensiq 996  18  19  815  18  39  34  48  73  15  14  
Koselugo  366  49  55  156  9  108  n/m n/m 74  93  93  
Kanuma 149  15  16  72  15  24  (1) 7  47  25  25  
Other medicines 824  (9) (4) 87  (17) 564  (3) 5  75  12  12  
Nexium 670  (9) (2) 77  (13) 458  -  9  40  12  10  
Others 154  (12) (10) 10  (35) 106  (13) (10) 35  13  13  
Total Product Sales 37,576  16  19  15,640  19  10,440  16  25  7,864  20  20  
 
 
Table 29: Q3 2024 - Product Sales year-on-year analysis15 
 
 World US Emerging Markets Europe 
 
 
$m Act % chg CER % chg $m % chg $m Act % chg CER % chg $m Act % chg CER % chg 
Oncology 5,197  18  21  2,484  25  1,145  18  28  1,032  22  22  
Tagrisso 1,674  14  17  714  24  446  9  16  328  17  17  
Imfinzi 1,203  13  16  680  19  120  40  66  236  16  16  
Calquence 813  24  25  570  22  41  47  70  169  32  32  
Lynparza 778  11  13  347  8  155  18  24  214  21  21  
Enhertu 148  n/m n/m -  -  97  n/m n/m 35  n/m n/m 
Zoladex 268  12  18  4  (34) 207  14  21  33  8  10  
Imjudo 72  20  22  46  15  4  n/m n/m 10  99  n/m 
Truqap 125  n/m n/m 119  n/m 1  -  -  2  -  -  
Orpathys 10  (16) (16) -  -  10  (16) (16) -  -  -  
Others 106  (10) (5) 4  2  64  (14) (8) 5  (27) (26) 
BioPharmaceuticals: CVRM 3,152  17  20  739  7  1,396  20  25  826  26  26  
Farxiga 1,938  25  27  411  12  750  30  35  670  32  32  
Brilinta 327  (1) (1) 189  (2) 66  3  6  67  (1) (1) 
Crestor 304  10  14  11  (18) 252  15  18  10  4  2  
Seloken/Toprol-XL 150  (2) 1  -  n/m 145  (3) 1  4  n/m 98  
Lokelma 143  40  42  66  28  26  99  n/m 25  61  61  
roxadustat 93  26  25  -  -  93  26  26  -  -  -  
Andexxa 54  36  38  19  (4) 1  n/m n/m 20  39  39  
Wainua 23  n/m n/m 23  n/m -  -  -  -  -  -  
Others 120  (22) (20) 20  (57) 63  3  6  30  (28) (26) 
BioPharmaceuticals: R&I 1,830  26  28  852  40  457  8  14  346  30  30  
Symbicort 705  27  31  289  86  203  4  13  130  5  6  
Fasenra 436  12  13  271  9  27  41  50  102  19  19  
Pulmicort 138  (6) (4) 5  7  110  (8) (5) 14  10  9  
Breztri 266  56  57  142  45  68  62  65  37  98  98  
Tezspire 68  n/m n/m -  -  3  n/m n/m 43  n/m n/m 
Saphnelo 124  63  64  110  55  3  n/m n/m 7  n/m n/m 
Airsupra 21  n/m n/m 21  n/m -  -  -  -  -  -  
Others 72  (21) (21) 14  (54) 43  (8) (8) 13  7  7  
BioPharmaceuticals: V&I 355  59  61  145  n/m 37  18  37  108  23  20  
Synagis 93  (6) 3  -  n/m 37  16  36  13  (19) (20) 
Beyfortus 134  n/m n/m 95  n/m -  -  -  39  n/m n/m 
FluMist 100  34  31  22  43  -  -  -  56  -  (3) 
COVID-19 mAbs 28  n/m n/m 28  n/m -  n/m n/m -  -  -  
Others -  n/m n/m -  -  -  -  -  -  -  -  
Rare Disease 2,148  9  11  1,325  12  174  7  29  395  -  -  
Ultomiris 1,031  33  35  597  34  26  53  84  238  30  30  
Soliris 606  (22) (18) 362  (14) 110  (11) 14  86  (47) (47) 
Strensiq 343  20  21  286  21  8  52  55  25  17  17  
Koselugo  119  37  39  55  2  25  n/m n/m 29  90  94  
Kanuma 49  10  9  25  11  5  (27) (29) 17  27  23  
Other medicines 265  (11) (7) 35  (3) 179  (6) -  22  18  16  
Nexium 212  (13) (9) 30  3  140  (9) (2) 14  31  29  
Others 53  -  (1) 5  (28) 39  7  8  8  (1) (1) 
Total Product Sales 12,947  18  20  5,580  23  3,388  15  23  2,729  20  20  
 
 
Table 30: Alliance Revenue  
 
  9M 2024  9M 2023  
  $m  $m  
Enhertu  1,045  741  
Tezspire  303  179  
Beyfortus  75  16  
Other Alliance Revenue  75  68  
 
15 The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to 
rounding, the sum of a number of dollar values and percentages may not agree to totals.

===== SIDA 38 =====

38 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
Total  1,498  1,004  
 
Table 31: Collaboration Revenue  
 
  9M 2024  9M 2023  
  $m  $m  
Farxiga: sales milestones  52  28  
Beyfortus: sales milestones  56  71  
COVID-19 mAbs licence fees  -  180  
Other Collaboration Revenue  -  38  
Total  108  317  
 
Table 32: Other operating income and expense 
 
  9M 2024  9M 2023  
  $m  $m  
brazikumab licence termination funding  -  75  
Divestment of US rights to Pulmicort Flexhaler  -  241  
Update to the contractual relationships for Beyfortus (nirsevimab)  -  712  
Other  152  205  
Total  152  1,233  
 
Other shareholder information 
 
Financial calendar 
 
Announcement of FY and Q4 2024 results: 6 February 2025 
Announcement of Q1 2025 results:  29 April 2025 
 
Dividends are normally paid as follows: 
 
First interim:  Announced with the half year results and paid in September 
Second interim: Announced with the full year results and paid in March 
 
Contacts 
 
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. 
 
Addresses for correspondence  
 
Registered office Registrar and 
transfer office 
Swedish Central 
Securities Depository 
US depositary 
Deutsche Bank Trust 
Company Americas 
1 Francis Crick Avenue 
Cambridge Biomedical 
Campus 
Cambridge 
CB2 0AA 
Equiniti Limited 
Aspect House 
Spencer Road 
Lancing 
West Sussex 
BN99 6DA 
Euroclear Sweden AB PO 
Box 191 
SE-101 23 Stockholm 
American Stock Transfer 
6201 15th Avenue 
Brooklyn 
NY 11219  
United Kingdom United Kingdom Sweden United States 
+44 (0) 20 3749 5000 0800 389 1580 +46 (0) 8 402 9000 +1 (888) 697 8018 
 +44 (0) 121 415 7033  +1 (718) 921 8137 
   db@astfinancial.com  
 
Trademarks 
 
Trademarks of the AstraZeneca group of companies appear throughout this document in italics. Medical 
publications also appear throughout the document in italics. AstraZeneca, the AstraZeneca logotype and the 
AstraZeneca symbol are all trademarks of the AstraZeneca group of companies. Trademarks of companies

===== SIDA 39 =====

39 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
other than AstraZeneca that appear in this document include : Beyfortus, a trademark of Sanofi Pasteur Inc.; 
Enhertu, a trademark of Daiichi Sankyo; Seloken, owned by AstraZeneca or Taiyo Pharma Co., Ltd (depending 
on geography); Synagis, owned by AstraZeneca or Sobi aka Swedish Orphan Biovitrum AB (publ). (depending 
on geography); and Tezspire, a trademark of Amgen, Inc. 
 
Information on or accessible through AstraZeneca 's websites, including  astrazeneca.com, does not form part 
of and is not incorporated into this announcement. 
 
AstraZeneca 
 
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the 
discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and 
BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in 
Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions 
of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca. 
 
Cautionary statements regarding forward-looking statements 
 
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform 
Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: 
 
This document contains certain forward -looking statements with respect to the operations, performance and 
financial condition of the Group, including, among other things, statements about expected revenues, margins, 
earnings per share or other financial or other measures. Although the Group believes its expectations are based 
on reasonable assumptions, any forward -looking statements, by their very nature, involve risks and 
uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially 
different from those predicted. The forwar d-looking statements reflect knowledge and information available at 
the date of preparation of this document and the Group undertakes no obligation to update these forward-looking 
statements. The Group identifies the forward -looking statements by using the words 'anticipates', 'believes', 
'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results 
to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's 
control, include, among other things: 
 
‒ the risk of failure or delay in delivery of pipeline or launch of new medicines 
‒ the risk of failure to meet regulatory or ethical requirements for medicine development or approval 
‒ the risk of failures or delays in the quality or execution of the Group's commercial strategies 
‒ the risk of pricing, affordability, access and competitive pressures 
‒ the risk of failure to maintain supply of compliant, quality medicines 
‒ the risk of illegal trade in the Group's medicines 
‒ the impact of reliance on third-party goods and services 
‒ the risk of failure in information technology or cybersecurity 
‒ the risk of failure of critical processes 
‒ the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic 
objectives 
‒ the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce 
‒ the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate 
change 
‒ the risk of the safety and efficacy of marketed medicines being questioned 
‒ the risk of adverse outcome of litigation and/or governmental investigations 
‒ intellectual property-related risks to the Group's products 
‒ the risk of failure to achieve strategic plans or meet targets or expectations 
‒ the risk of failure in financial control or the occurrence of fraud 
‒ the risk of unexpected deterioration in the Group's financial position 
‒ the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's 
ability to continue to mitigate these risks, and on the Group 's operations, financial results or financial 
condition 
 
Glossary

===== SIDA 40 =====

40 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
 
1L, 2L, etc First line, second line, etc 
ADC Antibody drug conjugate 
aHUS Atypical haemolytic uraemic syndrome 
AKT Protein kinase B 
AL amyloidosis Light chain amyloidosis 
ANDA Abbreviated New Drug Application (US) 
ASO Antisense oligonucleotide 
ATTR-CM Transthyretin-mediated amyloid cardiomyopathy 
ATTRv / -PN / -CM Hereditary transthyretin-mediated amyloid / polyneuropathy / cardiomyopathy 
BCMA B-cell maturation antigen 
BRCA / m Breast cancer gene / mutation 
BTC Biliary tract cancer 
BTK Bruton tyrosine kinase 
C5 Complement component 5 
CAR-T Chimeric antigen receptor T-cell 
cCRT Concurrent chemoradiotherapy 
CD19 A gene expressed in B-cells 
CER Constant exchange rates 
CHMP Committee for Medicinal Products for Human Use (EU) 
CI Confidence interval 
CKD Chronic kidney disease 
CLL Chronic lymphocytic leukaemia 
COPD Chronic obstructive pulmonary disease 
COP28 28th annual United Nations (UN) climate meeting 
CRC Colorectal cancer 
CRL Compete Response Letter 
CRPC Castration-resistant prostate cancer 
CSPC Castration-sensitive prostate cancer 
CTLA-4 Cytotoxic T-lymphocyte-associated antigen 4 
CVRM Cardiovascular, Renal and Metabolism 
DDR DNA damage response 
DNA Deoxyribonucleic acid 
EBITDA Earnings before interest, tax, depreciation and amortisation 
EGFR / m Epidermal growth factor receptor gene / mutation 
EGPA Eosinophilic granulomatosis with polyangiitis 
EPS Earnings per share 
ER Estrogen receptor  
ERBB2 v-erb-b2 avian erythroblastic leukaemia viral oncogene homologue 2 gene 
EVH Extravascular haemolysis 
FDA Food and Drug Agency (US) 
FDC Fixed dose combination 
FISH Fluorescence in situ hybridization, as in FISH10+  
g Germline, e.g. gBRCAm 
GAAP Generally Accepted Accounting Principles 
GEJ Gastro oesophageal junction 
GI Gastrointestinal 
GLP1 / -RA Glucagon-like peptide-1 / receptor agonist 
gMG Generalised myasthenia gravis 
HCC Hepatocellular carcinoma 
HER2 / +/- / low / m Human epidermal growth factor receptor 2 / positive / negative / low level expression / gene mutant 
HF/ pEF / rEF  Heart failure / with preserved ejection fraction / with reduced ejection fraction 
hMPV  Human metapneumovirus 
HR Hazard ratio 
HR / + / - Hormone receptor / positive / negative 
HRD Homologous recombination deficiency 
HRR / m Homologous recombination repair gene / mutation 
i.m. Intramuscular injection 
i.v. Intravenous injection 
IAS / B International Accounting  
Standards / Board 
ICS Inhaled corticosteroid

===== SIDA 41 =====

41 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
IFRS International Financial Reporting Standards 
IgAN Immunoglobulin A neuropathy 
IHC Immunohistochemistry, as in IHC90+, etc 
IL-5, IL-33, etc Interleukin-5, Interleukin-33, etc  
IP Intellectual Property 
IVIg Intravenous immune globulin 
LABA Long-acting beta-agonist 
LAMA Long-acting muscarinic-agonist 
LS-SCLC Limited stage small cell lung cancer 
LRTD Lower respiratory tract disease 
m Metastatic, e.g. mBTC , mCRPC, mCSPC  
mAb Monoclonal antibody 
MDL Multidistrict litigation 
MET Mesenchymal epithelial transition 
NF1-PN Neurofibromatosis type 1 with plexiform neurofibromas  
n/m Not meaningful 
NMOSD Neuromyelitis optica spectrum disorder 
NRDL National reimbursement drug list 
NSCLC Non-small cell lung cancer 
OECD Organisation for Economic  
Co-operation and Development 
OOI Other operating income 
ORR Overall response rate 
OS Overall survival 
PAAGR Post Alexion Acquisition Group Review 
PARP / i / -1sel Poly ADP ribose polymerase / inhibitor /-1 selective 
pCR Pathologic complete response 
PCSK9 Proprotein convertase subtilisin/kexin type 9  
PD Progressive disease 
PD-1 Programmed cell death protein 1 
PD-L1 Programmed cell death ligand 1 
PDUFA Prescription Drug User Fee Act 
PHSSR Partnership for Health System Sustainability and Resilience 
PFS Progression free survival 
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha gene 
PMDI Pressure metered dose inhaler 
PNH / -EVH Paroxysmal nocturnal haemoglobinuria / with extravascular haemolysis 
PPI Proton pump inhibitors 
PSR Platinum sensitive relapse 
PTEN Phosphatase and tensin homologue gene 
Q3W, Q4W, etc Every three weeks, every four weeks, etc 
R&D Research and development 
R&I Respiratory & Immunology 
RSV Respiratory syncytial virus 
sBLA Supplemental biologics license application (US) 
SCLC Small cell lung cancer 
s.c. Subcutaneous injection 
SEA Severe eosinophilic asthma 
SEC Securities Exchange Commission (US) 
SG&A Sales, general and administration 
SGLT2 Sodium-glucose cotransporter 2 
SLL Small lymphocytic lymphoma 
SMI Sustainable Markets Initiative 
sNDA Supplemental new drug application 
SPA Share Purchase Agreement 
T2D Type-2 diabetes 
TACE Transarterial chemoembolization 
THP A treatment regimen: docetaxel, trastuzumab and pertuzumab  
TNBC Triple negative breast cancer 
TNF Tumour necrosis factor 
TOP1 Topoisomerase I 
TROP2 Trophoblast cell surface antigen 2

===== SIDA 42 =====

42 
Glossary Total Revenue Sustainability Financial Performance  Research and Development Financial Statements 
USPTO US Patent and Trademark Office 
V&I Vaccines & Immune Therapies 
VBP Volume-based procurement 
VLP Virus like particle 
 
- End of document -